{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 4767, "items": [{"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T08:51:50Z", "timestamp": 1574758310374}, "reference-count": 38, "publisher": "Wiley", "issue": "8", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/100006483", "name": "AbbVie", "doi-asserted-by": "publisher", "award": ["NCT02068222"]}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Liver Int"], "published-print": {"date-parts": [[2016, 8]]}, "DOI": "10.1111/liv.13067", "type": "journal-article", "created": {"date-parts": [[2016, 1, 18]], "date-time": "2016-01-18T12:10:26Z", "timestamp": 1453119026000}, "page": "1125-1132", "source": "Crossref", "is-referenced-by-count": 9, "title": ["High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection"], "prefix": "10.1111", "volume": "36", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX USA"}]}, {"given": "Charles S.", "family": "Landis", "sequence": "additional", "affiliation": [{"name": "Division of Gastroenterology; University of Washington; Seattle WA USA"}]}, {"given": "Armen", "family": "Asatryan", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"suffix": "III", "given": "Daniel F.", "family": "Jackson", "sequence": "additional", "affiliation": [{"name": "Digestive Health Specialists of the Southeast; Dothan AL USA"}]}, {"given": "Teresa I.", "family": "Ng", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"given": "Bo", "family": "Fu", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"given": "Chih-Wei", "family": "Lin", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"given": "Betty", "family": "Yao", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"given": "Jens", "family": "Kort", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}], "member": "311", "published-online": {"date-parts": [[2016, 2, 3]]}, "reference": [{"key": "10.1111/liv.13067-BIB0001|liv13067-cit-0001", "doi-asserted-by": "crossref", "first-page": "1333", "DOI": "10.1002/hep.26141", "article-title": "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence", "volume": "57", "author": "Mohd Hanafiah", "year": "2013", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0002|liv13067-cit-0002", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1002/hep.27259", "article-title": "Global distribution and prevalence of hepatitis C virus genotypes", "volume": "61", "author": "Messina", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0003|liv13067-cit-0003", "doi-asserted-by": "crossref", "first-page": "686", "DOI": "10.1111/apt.12646", "article-title": "Review article: HCV genotype 3 - the new treatment challenge", "volume": "39", "author": "Ampuero", "year": "2014", "journal-title": "Aliment Pharmacol Ther"}, {"key": "10.1111/liv.13067-BIB0004|liv13067-cit-0004", "doi-asserted-by": "crossref", "first-page": "631", "DOI": "10.1001/jama.2014.7085", "article-title": "Treatment of hepatitis C: a systematic review", "volume": "312", "author": "Kohli", "year": "2014", "journal-title": "JAMA"}, {"key": "10.1111/liv.13067-BIB0005|liv13067-cit-0005", "doi-asserted-by": "crossref", "first-page": "131", "DOI": "10.1016/j.meegid.2004.08.001", "article-title": "The hepatitis C virus epidemic among injecting drug users", "volume": "5", "author": "Pybus", "year": "2005", "journal-title": "Infect, Genet Evol"}, {"key": "10.1111/liv.13067-BIB0006|liv13067-cit-0006", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.1086/524846", "article-title": "Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation", "volume": "197", "author": "Jhaveri", "year": "2008", "journal-title": "J Infect Dis"}, {"key": "10.1111/liv.13067-BIB0007|liv13067-cit-0007", "doi-asserted-by": "crossref", "first-page": "2403", "DOI": "10.1002/hep.26905", "article-title": "Is genotype 3 of the hepatitis C virus the new villain?", "volume": "59", "author": "Goossens", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0008|liv13067-cit-0008", "doi-asserted-by": "crossref", "first-page": "e516", "DOI": "10.1111/j.1365-2893.2011.01441.x", "article-title": "HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis", "volume": "18", "author": "Nkontchou", "year": "2011", "journal-title": "J Viral Hepatitis"}, {"key": "10.1111/liv.13067-BIB0009|liv13067-cit-0009", "doi-asserted-by": "crossref", "first-page": "525", "DOI": "10.1111/j.1365-2893.2012.01634.x", "article-title": "Hepatitis C therapy in non-genotype 1 patients: the near future", "volume": "19", "author": "Wartelle-Bladou", "year": "2012", "journal-title": "J Viral Hepatitis"}, {"key": "10.1111/liv.13067-BIB0010|liv13067-cit-0010", "doi-asserted-by": "crossref", "first-page": "669", "DOI": "10.1111/jvh.12168", "article-title": "Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3", "volume": "20", "author": "Tapper", "year": "2013", "journal-title": "J Viral Hepatitis"}, {"key": "10.1111/liv.13067-BIB0011|liv13067-cit-0011", "unstructured": "SOVALDI (sofosbuvir) Prescribing Information Gilead Sciences Foster City, CA 2014"}, {"key": "10.1111/liv.13067-BIB0012|liv13067-cit-0012", "unstructured": "DAKLINZA (daclatasvir) Summary of Product Characteristics Bristol-Myers Squibb Uxbridge, UK 2014"}, {"key": "10.1111/liv.13067-BIB0013|liv13067-cit-0013", "unstructured": "DAKLINZA (daclatasvir) Prescribing Information Bristol-Myers Squibb New York City, NY 2015"}, {"key": "10.1111/liv.13067-BIB0014|liv13067-cit-0014", "unstructured": "HARVONI (ledipasvir and sofosbuvir) Summary of Product Characteristics Gilead Sciences Cambridge, UK 2015"}, {"key": "10.1111/liv.13067-BIB0015|liv13067-cit-0015", "doi-asserted-by": "crossref", "first-page": "S187", "DOI": "10.1016/S0168-8278(15)30009-X", "article-title": "Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks of sofosbuvir and NS5A inhibitors with/without ribavirin is effective in genotypes 1 and 3", "volume": "62", "author": "Foster", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13067-BIB0016|liv13067-cit-0016", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1111/j.1365-2036.2008.03763.x", "article-title": "Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis", "volume": "28", "author": "Andriulli", "year": "2008", "journal-title": "Aliment Pharmacol Ther"}, {"key": "10.1111/liv.13067-BIB0017|liv13067-cit-0017", "doi-asserted-by": "crossref", "first-page": "1127", "DOI": "10.1002/hep.27726", "article-title": "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study", "volume": "61", "author": "Nelson", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0018|liv13067-cit-0018", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1056/NEJMoa1306218", "article-title": "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection", "volume": "370", "author": "Sulkowski", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13067-BIB0019|liv13067-cit-0019", "doi-asserted-by": "crossref", "first-page": "675", "DOI": "10.1007/s40265-015-0381-2", "article-title": "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C", "volume": "75", "author": "Keating", "year": "2015", "journal-title": "Drugs"}, {"key": "10.1111/liv.13067-BIB0020|liv13067-cit-0020", "unstructured": "Menon RM Klein CE Lawal AA et al Pharmacokinetics and Tolerability of the HCV Protease Inhibitor ABT-450 Following Single Ascending Doses in Healthy Adult Volunteers With and Without Ritonavir HepDART Kohala Coast, HI 2009"}, {"key": "10.1111/liv.13067-BIB0021|liv13067-cit-0021", "unstructured": "VIEKIRA PAK (ombitasvir, paritaprevir/ritonavir, dasabuvir) Prescribing Information AbbVie Inc. North Chicago, IL 2015"}, {"key": "10.1111/liv.13067-BIB0022|liv13067-cit-0022", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1016/j.jinf.2014.09.008", "article-title": "Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection", "volume": "70", "author": "Lawitz", "year": "2015", "journal-title": "J Infect"}, {"key": "10.1111/liv.13067-BIB0023|liv13067-cit-0023", "doi-asserted-by": "crossref", "first-page": "988", "DOI": "10.1128/AAC.04227-14", "article-title": "In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450", "volume": "59", "author": "Pilot-Matias", "year": "2015", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/liv.13067-BIB0024|liv13067-cit-0024", "doi-asserted-by": "crossref", "first-page": "979", "DOI": "10.1128/AAC.04226-14", "article-title": "In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an Inhibitor of HCV NS5A", "volume": "59", "author": "Krishnan", "year": "2014", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/liv.13067-BIB0025|liv13067-cit-0025", "unstructured": "Ng T Krishnan P Kati W et al ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance 21st Annual Conference on Retroviruses and Opportunistic Infections Boston 2014"}, {"key": "10.1111/liv.13067-BIB0026|liv13067-cit-0026", "doi-asserted-by": "crossref", "first-page": "S621", "DOI": "10.1016/S0168-8278(15)30979-X", "article-title": "P0776: Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients", "volume": "62", "author": "Gane", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13067-BIB0027|liv13067-cit-0027", "doi-asserted-by": "crossref", "first-page": "6807", "DOI": "10.1128/AAC.01229-15", "article-title": "Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir", "volume": "59", "author": "Schnell", "year": "2015", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/liv.13067-BIB0028|liv13067-cit-0028", "doi-asserted-by": "crossref", "first-page": "1546", "DOI": "10.1128/AAC.02264-15", "article-title": "Potent antiviral activity of direct-acting antivirals, ABT-493 and ABT-530, with 3-day monotherapy for hepatitis C genotype 1 infection", "volume": "60", "author": "Lawitz", "year": "2015", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/liv.13067-BIB0029|liv13067-cit-0029", "volume": "57", "first-page": "15", "year": "2015", "article-title": "A 4-drug combination (Viekira Pak) for hepatitis C", "journal-title": "Med Lett Drugs Ther"}, {"key": "10.1111/liv.13067-BIB0030|liv13067-cit-0030", "doi-asserted-by": "crossref", "first-page": "3595", "DOI": "10.1128/JCM.01320-07", "article-title": "Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the high pure system: enhanced genotype inclusivity and performance characteristics in a multisite study", "volume": "45", "author": "Colucci", "year": "2007", "journal-title": "J Clin Microbiol"}, {"key": "10.1111/liv.13067-BIB0031|liv13067-cit-0031", "unstructured": "Ng T Reisch T Middleton T et al ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotypic coverage 21st Annual Conference on Retroviruses and Opportunistic Infections Boston 2014"}, {"key": "10.1111/liv.13067-BIB0032|liv13067-cit-0032", "doi-asserted-by": "crossref", "first-page": "192", "DOI": "10.1016/j.jhep.2011.01.011", "article-title": "Hepatitis C virus resistance to protease inhibitors", "volume": "55", "author": "Halfon", "year": "2011", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13067-BIB0033|liv13067-cit-0033", "first-page": "1142A", "article-title": "A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT-493 and ABT-530 with high barriers to resistance", "volume": "60", "author": "Ng", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0034|liv13067-cit-0034", "doi-asserted-by": "crossref", "first-page": "2902", "DOI": "10.3748/wjg.v20.i11.2902", "article-title": "Hepatitis C virus NS5A inhibitors and drug resistance mutations", "volume": "20", "author": "Nakamoto", "year": "2014", "journal-title": "World J Gastroenterol"}, {"key": "10.1111/liv.13067-BIB0035|liv13067-cit-0035", "unstructured": "National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) 2009 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"}, {"key": "10.1111/liv.13067-BIB0036|liv13067-cit-0036", "first-page": "1128A", "article-title": "Potent antiviral activity of ABT-493 and ABT-530 with 3-day monotherapy in patients with and without compensated cirrhosis with hepatitis C virus (HCV) genotype 1 infection", "volume": "60", "author": "Lawitz", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0037|liv13067-cit-0037", "first-page": "236A", "article-title": "Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study. Abstract #79", "volume": "60", "author": "Gane", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13067-BIB0038|liv13067-cit-0038", "doi-asserted-by": "crossref", "first-page": "S187", "DOI": "10.1016/S0168-8278(15)30013-1", "article-title": "C-SWIFT: Grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhoitic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6, or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks", "volume": "62", "author": "Poordad", "year": "2015", "journal-title": "J Hepatol"}], "container-title": ["Liver International"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fliv.13067", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T03:57:07Z", "timestamp": 1498276627000}, "score": 91.05553, "issued": {"date-parts": [[2016, 2, 3]]}, "references-count": 38, "journal-issue": {"published-print": {"date-parts": [[2016, 8]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1111/liv.13067", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1478-3223"], "issn-type": [{"value": "1478-3223", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T01:13:28Z", "timestamp": 1574558008410}, "reference-count": 16, "publisher": "Oxford University Press (OUP)", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2015, 2, 15]]}, "DOI": "10.1093/cid/ciu865", "type": "journal-article", "created": {"date-parts": [[2014, 11, 4]], "date-time": "2014-11-04T06:23:40Z", "timestamp": 1415082220000}, "page": "608-610", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study"], "prefix": "10.1093", "volume": "60", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "Kosh", "family": "Agarwal", "sequence": "additional", "affiliation": []}, {"given": "Ziad", "family": "Younes", "sequence": "additional", "affiliation": []}, {"given": "Daniel", "family": "Cohen", "sequence": "additional", "affiliation": []}, {"given": "Wangang", "family": "Xie", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Podsadecki", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2014, 11, 2]]}, "reference": [{"key": "key\n\t\t\t\t20170522093600_CIU865C1", "volume": "10", "first-page": "553", "year": "2013", "article-title": "Epidemiology and natural history of HCV infection", "journal-title": "Nat Rev Gastroenterol Hepatol", "DOI": "10.1038/nrgastro.2013.107", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C2", "volume": "17", "first-page": "107", "year": "2011", "article-title": "Evolving epidemiology of hepatitis C virus", "journal-title": "Clin Microbiol Infect", "DOI": "10.1111/j.1469-0691.2010.03432.x", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C3", "volume": "144", "first-page": "1450", "year": "2013", "article-title": "Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies", "journal-title": "Gastroenterology", "DOI": "10.1053/j.gastro.2013.02.039", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C4", "volume": "51", "first-page": "1122", "year": "2010", "article-title": "Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin", "journal-title": "Hepatology", "DOI": "10.1002/hep.23444", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C5", "volume": "39", "first-page": "106", "year": "2003", "article-title": "Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C", "journal-title": "J Hepatol", "DOI": "10.1016/S0168-8278(03)00187-9", "doi-asserted-by": "crossref"}, {"issue": "suppl 1", "key": "key\n\t\t\t\t20170522093600_CIU865C6", "first-page": "S348", "article-title": "High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir", "volume": "58", "year": "2013", "journal-title": "J Hepatol"}, {"issue": "suppl 1", "key": "key\n\t\t\t\t20170522093600_CIU865C7", "first-page": "138A", "article-title": "The concordance between SVR4, SVR12, and SVR24 in patients with chronic HCV infection who received treatment with sofosbuvir in phase 3 clinical trials", "volume": "58", "year": "2013", "journal-title": "Hepatology"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C8", "volume": "58", "first-page": "1516", "year": "2013", "article-title": "Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study", "journal-title": "Hepatology", "DOI": "10.1002/hep.26363", "doi-asserted-by": "crossref"}, {"issue": "suppl 1", "key": "key\n\t\t\t\t20170522093600_CIU865C9", "first-page": "569A", "article-title": "SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127", "volume": "56", "year": "2012", "journal-title": "Hepatology"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C10", "year": "2014", "volume-title": "Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 American Association for the Study of Liver Diseases treatment guidelines"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C11", "volume": "370", "first-page": "222", "year": "2014", "article-title": "Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJMoa1306227", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C12", "volume": "108", "first-page": "515", "year": "2011", "article-title": "Concordance analysis: part 16 of a series on evaluation of scientific publications", "journal-title": "Dtsch Arztebl Int"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C13", "volume": "52", "first-page": "889", "year": "2011", "article-title": "Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more", "journal-title": "Clin Infect Dis", "DOI": "10.1093/cid/cir076", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C14", "volume": "384", "first-page": "403", "year": "2014", "article-title": "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(14)60494-3", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C15", "volume": "384", "first-page": "414", "year": "2014", "article-title": "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(14)60538-9", "doi-asserted-by": "crossref"}, {"key": "key\n\t\t\t\t20170522093600_CIU865C16", "author": "Olysio (simeprevir) [package insert]", "year": "2013", "article-title": "Janssen Therapeutics"}], "container-title": ["Clinical Infectious Diseases"], "language": "en", "deposited": {"date-parts": [[2017, 6, 22]], "date-time": "2017-06-22T23:32:43Z", "timestamp": 1498174363000}, "score": 48.97885, "issued": {"date-parts": [[2014, 11, 2]]}, "references-count": 16, "journal-issue": {"published-online": {"date-parts": [[2014, 11, 2]]}, "published-print": {"date-parts": [[2015, 2, 15]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1093/cid/ciu865", "relation": {"cites": []}, "ISSN": ["1058-4838", "1537-6591"], "issn-type": [{"value": "1058-4838", "type": "print"}, {"value": "1537-6591", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:29:39Z", "timestamp": 1574414979630}, "publisher-location": "Oxford, UK", "reference-count": 32, "publisher": "Wiley-Blackwell", "isbn-type": [{"value": "9781405187459", "type": "print"}, {"value": "9781444346343", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781444346343.ch5", "type": "book-chapter", "created": {"date-parts": [[2011, 11, 3]], "date-time": "2011-11-03T17:30:12Z", "timestamp": 1320341412000}, "page": "36-42", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs"], "prefix": "10.1002", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "Grace M.", "family": "Chee", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 11, 3]]}, "reference": [{"key": "10.1002/9781444346343.ch5-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1177/095632020101200501", "article-title": "Mechanisms of action of ribavirin in antiviral therapies", "volume": "12", "author": "Tam", "year": "2002", "journal-title": "Antiviral Chem Chemother"}, {"key": "10.1002/9781444346343.ch5-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "376", "DOI": "10.1016/S0168-8278(99)80093-2", "article-title": "Ribavirin polarized human T cell response towards a Type 1 cytokine profile", "volume": "30", "author": "Tam", "year": "1999", "journal-title": "J Hepatol"}, {"key": "10.1002/9781444346343.ch5-BIB3|cit3", "first-page": "2381", "article-title": "The antiviral compound ribavirin modulates the T helper (Th) 1/Th 2 subset balance in hepatitis B and C virus-specific immune responses", "volume": "79", "author": "Hultgren", "year": "1998", "journal-title": "J GenVirol"}, {"key": "10.1002/9781444346343.ch5-BIB4|cit4", "first-page": "1315", "article-title": "Ribavirin in the treatment of hepatitis C", "volume": "25", "author": "Abonyi", "year": "2005", "journal-title": "Anticancer Res"}, {"key": "10.1002/9781444346343.ch5-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "3382", "DOI": "10.1128/AAC.48.9.3382-3389.2004", "article-title": "Impact of alpha interferon and ribavirin on the function of maturing dendritic cells", "volume": "48", "author": "Barnes", "year": "2004", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1002/9781444346343.ch5-BIB6|cit6", "first-page": "50", "article-title": "Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection", "volume": "69", "author": "Meier", "year": "2003", "journal-title": "J MedVirol"}, {"key": "10.1002/9781444346343.ch5-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "842", "DOI": "10.1111/j.1572-0241.2006.00505.x", "article-title": "Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials", "volume": "101", "author": "Brok", "year": "2006", "journal-title": "Am J Gastroenterol"}, {"key": "10.1002/9781444346343.ch5-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "703", "DOI": "10.1053/j.gastro.2003.12.002", "article-title": "Antiviral action of ribavirin in chronic hepatitis C", "volume": "126", "author": "Pawlotsky", "year": "2004", "journal-title": "Gastroenterology"}, {"key": "10.1002/9781444346343.ch5-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "623", "DOI": "10.1016/j.jhep.2005.05.032", "article-title": "Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C", "volume": "43", "author": "Asahina", "year": "2005", "journal-title": "J Hepatol"}, {"key": "10.1002/9781444346343.ch5-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "921", "DOI": "10.1053/j.gastro.2006.12.005", "article-title": "Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy", "volume": "132", "author": "Hofmann", "year": "2007", "journal-title": "Gastroenterology"}, {"issue": "21", "key": "10.1002/9781444346343.ch5-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1485", "DOI": "10.1056/NEJM199811193392101", "article-title": "Inter-feron alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group", "volume": "339", "author": "McHutchison", "year": "1998", "journal-title": "N Engl J Med"}, {"key": "10.1002/9781444346343.ch5-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "958", "DOI": "10.1016/S0140-6736(01)06102-5", "article-title": "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", "volume": "358", "author": "Manns", "year": "2001", "journal-title": "Lancet"}, {"key": "10.1002/9781444346343.ch5-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "975", "DOI": "10.1056/NEJMoa020047", "article-title": "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", "volume": "347", "author": "Fried", "year": "2002", "journal-title": "NEnglJMed"}, {"issue": "18", "key": "10.1002/9781444346343.ch5-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "1827", "DOI": "10.1056/NEJMoa0806104", "article-title": "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection", "volume": "360", "author": "McHutchison", "year": "2009", "journal-title": "NEnglJMed"}, {"issue": "Suppl 1", "key": "10.1002/9781444346343.ch5-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "S4", "DOI": "10.1016/S0168-8278(09)60006-4", "article-title": "HCV SPRINT-1: Final results SVR 24 NS3 protease inhibitor boceprevir plus PegIFN alpha-2b/ribavirin HCV 1 treatment na\u00efve patients", "volume": "50", "author": "Kwo", "year": "2009", "journal-title": "J Hepatol"}, {"key": "10.1002/9781444346343.ch5-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1016/j.cgh.2006.10.008", "article-title": "Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment", "volume": "5", "author": "Reddy", "year": "2007", "journal-title": "Clin Gastoenterol Hepatol"}, {"issue": "6", "key": "10.1002/9781444346343.ch5-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "580", "DOI": "10.1056/NEJMoa0808010", "article-title": "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", "volume": "361", "author": "McHutchison", "year": "2009", "journal-title": "NEnglJMed"}, {"issue": "18", "key": "10.1002/9781444346343.ch5-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "1839", "DOI": "10.1056/NEJMoa0807650", "article-title": "Telaprevir and peginterferon with or without ribavirn for chronic HCV infection", "volume": "360", "author": "H\u00e9zode", "year": "2009", "journal-title": "NEnglJMed"}, {"key": "10.1002/9781444346343.ch5-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.1093/jac/dkg046", "article-title": "Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys", "volume": "51", "author": "Lin", "year": "2003", "journal-title": "J Antimicrob Chemother"}, {"issue": "4 Pt 2", "key": "10.1002/9781444346343.ch5-BIB20|cit20", "first-page": "327A", "article-title": "Phase I clinical studies of levovrin - a second generation ribavirin candidate", "volume": "34", "author": "Rossi", "year": "2001", "journal-title": "Hepatology"}, {"key": "10.1002/9781444346343.ch5-BIB21|cit21", "first-page": "H17 A32", "article-title": "Combination of levovirin and pegylated interferon alfa-2a fails to generate an induction response comparable to ribavirin and pegylated interferon alfa-2a in patients with CHC", "volume": "9", "author": "Pockros", "year": "2004", "journal-title": "Antivir Ther"}, {"key": "10.1002/9781444346343.ch5-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "921", "DOI": "10.1053/j.gastro.2006.12.005", "article-title": "Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy", "volume": "132", "author": "Hofmann", "year": "2007", "journal-title": "Gastroenterology"}, {"key": "10.1002/9781444346343.ch5-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "578", "DOI": "10.1177/0091270005274861", "article-title": "Single- and multiple-dose pharmacokinetics of levorin valinate hydrochloride (R1518) in healthy volunteers", "volume": "45", "author": "Huang", "year": "2005", "journal-title": "J Clin Pharmacol"}, {"issue": "1", "key": "10.1002/9781444346343.ch5-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "426", "DOI": "10.1128/AAC.47.1.426-431.2003", "article-title": "Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions", "volume": "47", "author": "Wu", "year": "2003", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1002/9781444346343.ch5-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "2458", "DOI": "10.1128/AAC.47.8.2458-2463.2003", "article-title": "Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys", "volume": "47", "author": "Lin", "year": "2003", "journal-title": "Antimicrobial Agents Chemother"}, {"key": "10.1002/9781444346343.ch5-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "145", "DOI": "10.1177/095632020301400304", "article-title": "Taribavirin, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals", "volume": "14", "author": "Lin", "year": "2003", "journal-title": "Anitviral Chem Chemother"}, {"issue": "2", "key": "10.1002/9781444346343.ch5-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "113", "DOI": "10.2217/17460794.4.2.113", "article-title": "Taribavirin: a potential alternative to ribavirin", "volume": "4", "author": "Poordad", "year": "2009", "journal-title": "Future Virol"}, {"issue": "3", "key": "10.1002/9781444346343.ch5-BIB28|cit28", "first-page": "265", "article-title": "Pharmacokineticsandsafety of viramidine, a prodrug of ribavirin, in healthy volunteers", "volume": "44", "author": "Lin", "year": "2004", "journal-title": "JClinPharmacol"}, {"key": "10.1002/9781444346343.ch5-BIB29|cit29", "first-page": "275", "article-title": "Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection", "volume": "45", "author": "Aora", "year": "2005", "journal-title": "JClinPharmacol"}, {"issue": "4", "key": "10.1002/9781444346343.ch5-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "1208", "DOI": "10.1002/hep.23827", "article-title": "Virologic response rates of weight-based taribavirin versus ribavirin in treatment-na\u00efve patients with genotype 1 chronic hepatitis C", "volume": "52", "author": "Poordad", "year": "2010", "journal-title": "Hepatology"}, {"issue": "4", "key": "10.1002/9781444346343.ch5-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "859", "DOI": "10.1128/AAC.44.4.859-866.2000", "article-title": "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon", "volume": "44", "author": "Markland", "year": "2000", "journal-title": "Antimicrob Agents Chemother"}, {"issue": "6", "key": "10.1002/9781444346343.ch5-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "1719", "DOI": "10.1002/hep.23204", "article-title": "Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders", "volume": "50", "author": "Rustgi", "year": "2009", "journal-title": "Herpatology"}], "container-title": ["Advanced Therapy for Hepatitis C"], "deposited": {"date-parts": [[2019, 6, 19]], "date-time": "2019-06-19T01:48:17Z", "timestamp": 1560908897000}, "score": 46.235878, "issued": {"date-parts": [[2011, 11, 3]]}, "ISBN": ["9781444346343", "9781405187459"], "references-count": 32, "URL": "http://dx.doi.org/10.1002/9781444346343.ch5", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T05:14:39Z", "timestamp": 1575436479790}, "reference-count": 8, "publisher": "Wiley", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2019, 5, 6]], "date-time": "2019-05-06T00:00:00Z", "timestamp": 1557100800000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/100006483", "name": "AbbVie", "doi-asserted-by": "publisher", "award": ["NCT02609659"]}], "content-domain": {"domain": ["onlinelibrary.wiley.com"], "crossmark-restriction": true}, "short-container-title": ["J Viral Hepat"], "DOI": "10.1111/jvh.13109", "type": "journal-article", "created": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T11:18:28Z", "timestamp": 1555154308000}, "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low\u2010dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis"], "prefix": "10.1111", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": [{"name": "Texas Liver Institute University of Texas Health San Antonio Texas"}]}, {"given": "Shahriar", "family": "Sedghi", "sequence": "additional", "affiliation": [{"name": "Mercer University School of Medicine Macon Georgia"}]}, {"given": "Paul J.", "family": "Pockros", "sequence": "additional", "affiliation": [{"name": "Division of Gastroenterology/Hepatology Scripps Clinic La Jolla California"}]}, {"given": "Natarajan", "family": "Ravendhran", "sequence": "additional", "affiliation": [{"name": "Digestive Disease Associates Baltimore Maryland"}]}, {"given": "Robert", "family": "Reindollar", "sequence": "additional", "affiliation": [{"name": "Piedmont Healthcare/Carolinas Center for Liver Disease Statesville North Carolina"}]}, {"given": "Michael R.", "family": "Lucey", "sequence": "additional", "affiliation": [{"name": "Division of Gastroenterology/Hepatology, Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin"}]}, {"given": "Michael", "family": "Epstein", "sequence": "additional", "affiliation": [{"name": "Anne Arundel Medical Center Digestive Disorders Associates Annapolis Maryland"}]}, {"given": "Leslie", "family": "Bank", "sequence": "additional", "affiliation": [{"name": "Regional Clinical Research Inc Endwell New York"}]}, {"given": "David", "family": "Bernstein", "sequence": "additional", "affiliation": [{"name": "Hofstra Northwell School of Medicine Manhasset New York"}]}, {"given": "Roger", "family": "Trinh", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc. North Chicago Illinois"}]}, {"given": "Preethi", "family": "Krishnan", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc. North Chicago Illinois"}]}, {"given": "Akshanth R.", "family": "Polepally", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc. North Chicago Illinois"}]}, {"given": "Kristina", "family": "Unnebrink", "sequence": "additional", "affiliation": [{"name": "AbbVie Deutschland GmbH &amp; Co. KG Ludwigshafen Germany"}]}, {"given": "Marisol", "family": "Martinez", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc. North Chicago Illinois"}]}, {"given": "David R.", "family": "Nelson", "sequence": "additional", "affiliation": [{"name": "Department of Medicine University of Florida Gainesville Florida"}]}], "member": "311", "published-online": {"date-parts": [[2019, 5, 6]]}, "reference": [{"key": "e_1_2_7_2_1", "unstructured": "AASLD\u2010IDSA.Recommendations for testing managing and treating hepatitis C.http://www.hcvguidelines.org. Accessed: June 19 2018."}, {"issue": "1", "key": "e_1_2_7_3_1", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1111/liv.13212", "article-title": "Ribavirin revisited in the era of direct\u2010acting antiviral therapy for hepatitis C virus infection", "volume": "37", "author": "Feld JJ", "year": "2017", "journal-title": "Liver Int"}, {"issue": "5", "key": "e_1_2_7_4_1", "doi-asserted-by": "crossref", "first-page": "1035", "DOI": "10.1053/j.gastro.2013.07.051", "article-title": "Effects of ribavirin dose reduction vs erythropoietin for boceprevir\u2010related anemia in patients with chronic hepatitis C virus genotype 1 infection\u2013a randomized trial", "volume": "145", "author": "Poordad F", "year": "2013", "journal-title": "Gastroenterology"}, {"issue": "21", "key": "e_1_2_7_5_1", "doi-asserted-by": "crossref", "first-page": "1983", "DOI": "10.1056/NEJMoa1402338", "article-title": "ABT\u2010450/r\u2010ombitasvir and dasabuvir with or without ribavirin for HCV", "volume": "370", "author": "Ferenci P", "year": "2014", "journal-title": "N Engl J Med"}, {"issue": "25", "key": "e_1_2_7_6_1", "doi-asserted-by": "crossref", "first-page": "2375", "DOI": "10.1056/NEJMoa1408921", "article-title": "An interferon\u2010free antiviral regimen for HCV after liver transplantation", "volume": "371", "author": "Kwo PY", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "e_1_2_7_7_1", "first-page": "137", "article-title": "Once\u2010daily dose regimen of ribavirin is interchangeable with a twice\u2010daily dose regimen: randomized open clinical trial", "volume": "8", "author": "Balk JM", "year": "2015", "journal-title": "Pharmgenomics Pers Med"}, {"issue": "17", "key": "e_1_2_7_8_1", "doi-asserted-by": "crossref", "first-page": "1594", "DOI": "10.1056/NEJMoa1315722", "article-title": "Treatment of HCV with ABT\u2010450/r\u2010ombitasvir and dasabuvir with ribavirin", "volume": "370", "author": "Feld JJ", "year": "2014", "journal-title": "N Engl J Med"}, {"issue": "21", "key": "e_1_2_7_9_1", "doi-asserted-by": "crossref", "first-page": "1973", "DOI": "10.1056/NEJMoa1402869", "article-title": "ABT\u2010450/r\u2010ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis", "volume": "370", "author": "Poordad F", "year": "2014", "journal-title": "N Engl J Med"}], "container-title": ["Journal of Viral Hepatitis"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjvh.13109", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13109", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jvh.13109", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13109", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 7]], "date-time": "2019-05-07T02:42:44Z", "timestamp": 1557196964000}, "score": 44.07756, "issued": {"date-parts": [[2019, 5, 6]]}, "references-count": 8, "alternative-id": ["10.1111/jvh.13109"], "URL": "http://dx.doi.org/10.1111/jvh.13109", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1352-0504", "1365-2893"], "issn-type": [{"value": "1352-0504", "type": "print"}, {"value": "1365-2893", "type": "electronic"}], "subject": ["Hepatology", "Virology", "Infectious Diseases"], "article-number": "jvh.13109"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T21:18:00Z", "timestamp": 1574284680752}, "reference-count": 20, "publisher": "SAGE Publications", "issue": "2", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2009, 3, 1]], "date-time": "2009-03-01T00:00:00Z", "timestamp": 1235865600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Therap Adv Gastroenterol"], "published-print": {"date-parts": [[2009, 3]]}, "DOI": "10.1177/1756283x08101217", "type": "journal-article", "created": {"date-parts": [[2009, 3, 9]], "date-time": "2009-03-09T16:24:12Z", "timestamp": 1236615852000}, "page": "91-97", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients"], "prefix": "10.1177", "volume": "2", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": [{"name": "Cedars Sinai Medical Center \u2014 Medicine, Los Angeles, CA, USA,"}]}, {"given": "Carmen", "family": "Landaverde", "sequence": "additional", "affiliation": [{"name": "UCLA, Medicine, Los Angeles, CA, USA"}]}], "member": "179", "published-online": {"date-parts": [[2009, 3]]}, "reference": [{"key": "atypb1", "DOI": "10.1053/j.gastro.2006.02.015", "doi-asserted-by": "publisher"}, {"key": "atypb2", "DOI": "10.1111/j.1365-2893.2006.00779.x", "doi-asserted-by": "publisher"}, {"key": "atypb3", "DOI": "10.1053/jhep.2003.50364", "doi-asserted-by": "publisher"}, {"key": "atypb4", "DOI": "10.1056/NEJMoa020047", "doi-asserted-by": "publisher"}, {"key": "atypb5", "DOI": "10.7326/0003-4819-140-5-200403020-00010", "doi-asserted-by": "publisher"}, {"key": "atypb6", "DOI": "10.1002/hep.21159", "doi-asserted-by": "publisher"}, {"key": "atypb7", "DOI": "10.1016/S0168-8278(02)00211-8", "doi-asserted-by": "publisher"}, {"key": "atypb8", "DOI": "10.1002/hep.22061", "doi-asserted-by": "publisher"}, {"key": "atypb9", "DOI": "10.1016/S0140-6736(01)06102-5", "doi-asserted-by": "publisher"}, {"key": "atypb10", "author": "Marcellin, P.", "volume": "46", "first-page": "818A", "year": "2007", "journal-title": "Hepatology"}, {"key": "atypb11", "DOI": "10.1136/gut.2006.106690", "doi-asserted-by": "publisher"}, {"key": "atypb12", "DOI": "10.1002/hep.21919", "doi-asserted-by": "publisher"}, {"key": "atypb13", "DOI": "10.1086/523585", "doi-asserted-by": "publisher"}, {"key": "atypb14", "DOI": "10.1053/j.gastro.2006.05.016", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "atypb15", "first-page": "A384", "volume": "44", "author": "Segadas-Soares, J.A.", "year": "2006", "journal-title": "Hepatology"}, {"key": "atypb16", "author": "Sulkowski M.", "volume-title": "Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver"}, {"issue": "4", "key": "atypb17", "first-page": "A1868", "volume": "48", "author": "Sulkowski, M.", "year": "2008", "journal-title": "Hepatology"}, {"key": "atypb18", "DOI": "10.1056/NEJMoa040842", "doi-asserted-by": "publisher"}, {"key": "atypb19", "DOI": "10.1002/hep.22319", "doi-asserted-by": "publisher"}, {"key": "atypb20", "DOI": "10.1016/j.jhep.2005.10.003", "doi-asserted-by": "publisher"}], "container-title": ["Therapeutic Advances in Gastroenterology"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/1756283X08101217", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/1756283X08101217", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 9, 19]], "date-time": "2018-09-19T14:37:40Z", "timestamp": 1537367860000}, "score": 41.00155, "issued": {"date-parts": [[2009, 3]]}, "references-count": 20, "journal-issue": {"published-online": {"date-parts": [[2009, 3]]}, "published-print": {"date-parts": [[2009, 3]]}, "issue": "2"}, "alternative-id": ["10.1177/1756283X08101217"], "URL": "http://dx.doi.org/10.1177/1756283x08101217", "relation": {"cites": []}, "ISSN": ["1756-283X", "1756-2848"], "issn-type": [{"value": "1756-283X", "type": "print"}, {"value": "1756-2848", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T22:51:35Z", "timestamp": 1575413495184}, "reference-count": 19, "publisher": "Wiley", "issue": "7", "license": [{"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2019, 3, 19]], "date-time": "2019-03-19T00:00:00Z", "timestamp": 1552953600000}, "delay-in-days": 0, "content-version": "vor"}, {"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2019, 3, 19]], "date-time": "2019-03-19T00:00:00Z", "timestamp": 1552953600000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/100006483", "name": "AbbVie", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": ["onlinelibrary.wiley.com"], "crossmark-restriction": true}, "short-container-title": ["J Med Virol"], "published-print": {"date-parts": [[2019, 7]]}, "DOI": "10.1002/jmv.25448", "type": "journal-article", "created": {"date-parts": [[2019, 3, 6]], "date-time": "2019-03-06T18:49:58Z", "timestamp": 1551898198000}, "page": "1307-1312", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct\u2010acting antiviral therapy"], "prefix": "10.1002", "volume": "91", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": [{"name": "The Texas Liver Institute/University of Texas HealthSan Antonio Texas"}]}, {"given": "Michael", "family": "Bennett", "sequence": "additional", "affiliation": [{"name": "Medical Associates Research GroupSan Diego California"}]}, {"given": "Thomas E.", "family": "Sepe", "sequence": "additional", "affiliation": [{"name": "Liver Center, University GastroenterologyProvidence Rhode Island"}]}, {"given": "Eric", "family": "Cohen", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.North Chicago Illinois"}]}, {"given": "Robert W.", "family": "Reindollar", "sequence": "additional", "affiliation": [{"name": "Piedmont Healthcare/Carolinas Center for Liver DiseaseStatesville North Carolina"}]}, {"given": "Gregory", "family": "Everson", "sequence": "additional", "affiliation": [{"name": "Division of Gastroenterology and HepatologyUniversity of Colorado Denver School of MedicineAurora Colorado"}]}, {"given": "Raymond W.", "family": "Phillips", "sequence": "additional", "affiliation": [{"name": "Gastroenterology Group of Naples PANaples Florida"}]}, {"given": "Asma", "family": "Siddique", "sequence": "additional", "affiliation": [{"name": "Digestive Disease InstituteVirginia Mason Hospital and Medical CenterSeattle Washington"}]}, {"given": "J. Greg", "family": "Sullivan", "sequence": "additional", "affiliation": [{"name": "Parkway Medical CenterBirmingham Alabama"}]}, {"given": "Tami", "family": "Pilot\u2010Matias", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.North Chicago Illinois"}]}, {"given": "Manal", "family": "Abunimeh", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.North Chicago Illinois"}]}, {"given": "Daniel E.", "family": "Cohen", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.North Chicago Illinois"}]}, {"ORCID": "http://orcid.org/0000-0001-7382-3698", "authenticated-orcid": false, "given": "Ziad", "family": "Younes", "sequence": "additional", "affiliation": [{"name": "GastroOneGermantown Tennessee"}]}], "member": "311", "published-online": {"date-parts": [[2019, 3, 19]]}, "reference": [{"key": "e_1_2_7_1_2_1", "DOI": "10.1038/nrdp.2017.6", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_3_1", "DOI": "10.1016/j.jhep.2015.08.015", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_4_1", "DOI": "10.1016/j.jhep.2015.10.005", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_5_1", "DOI": "10.1053/j.gastro.2016.04.003", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_6_1", "DOI": "10.1016/S0168-8278(15)30071-4", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_7_1", "unstructured": "MAVIRET\u00a0(glecaprevir/pibrentasvir) [package insert] package insert. AbbVie Inc. North Chicago IL USA."}, {"key": "e_1_2_7_1_8_1", "unstructured": "VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) [package insert]. Gilead Sciences. Foster City CA USA."}, {"key": "e_1_2_7_1_9_1", "DOI": "10.1053/j.gastro.2017.11.007", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_10_1", "DOI": "10.3851/IMP3053", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_11_1", "DOI": "10.1093/infdis/jiv564", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_12_1", "DOI": "10.1128/AAC.01913-15", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_13_1", "DOI": "10.1093/cid/cix916", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_14_1", "DOI": "10.1002/hep.28877", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_15_1", "DOI": "10.1002/hep.29256", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_16_1", "DOI": "10.1002/hep.29130", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_17_1", "DOI": "10.1002/hep.29081", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_18_1", "DOI": "10.1056/NEJMoa1613512", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_19_1", "DOI": "10.1002/hep.29671", "doi-asserted-by": "publisher"}, {"key": "e_1_2_7_1_20_1", "DOI": "10.1007/s00535-017-1396-0", "doi-asserted-by": "publisher"}], "container-title": ["Journal of Medical Virology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjmv.25448", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25448", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.25448", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25448", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 16]], "date-time": "2019-05-16T03:43:10Z", "timestamp": 1557978190000}, "score": 40.995422, "issued": {"date-parts": [[2019, 3, 19]]}, "references-count": 19, "journal-issue": {"published-online": {"date-parts": [[2019, 3, 4]]}, "published-print": {"date-parts": [[2019, 7]]}, "issue": "7"}, "alternative-id": ["10.1002/jmv.25448"], "URL": "http://dx.doi.org/10.1002/jmv.25448", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0146-6615", "1096-9071"], "issn-type": [{"value": "0146-6615", "type": "print"}, {"value": "1096-9071", "type": "electronic"}], "subject": ["Virology", "Infectious Diseases"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T02:49:46Z", "timestamp": 1574736586916}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 11, 1]], "date-time": "2015-11-01T00:00:00Z", "timestamp": 1446336000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinics in Liver Disease"], "published-print": {"date-parts": [[2015, 11]]}, "DOI": "10.1016/s1089-3261(15)00089-6", "type": "journal-article", "created": {"date-parts": [[2015, 10, 19]], "date-time": "2015-10-19T01:46:01Z", "timestamp": 1445219161000}, "page": "i", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Current Management of Hepatitis C Virus"], "prefix": "10.1016", "volume": "19", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Clinics in Liver Disease"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1089326115000896?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1089326115000896?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 18]], "date-time": "2018-09-18T17:51:08Z", "timestamp": 1537293068000}, "score": 39.34882, "issued": {"date-parts": [[2015, 11]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 11]]}, "issue": "4"}, "alternative-id": ["S1089326115000896"], "URL": "http://dx.doi.org/10.1016/s1089-3261(15)00089-6", "ISSN": ["1089-3261"], "issn-type": [{"value": "1089-3261", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T10:40:33Z", "timestamp": 1575456033700}, "reference-count": 0, "publisher": "Baishideng Publishing Group Inc.", "issue": "18", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["WJG"], "published-print": {"date-parts": [[2019, 5, 14]]}, "DOI": "10.3748/wjg.v25.i18.2229", "type": "journal-article", "created": {"date-parts": [[2019, 5, 14]], "date-time": "2019-05-14T07:28:58Z", "timestamp": 1557818938000}, "page": "2229-2239", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients"], "prefix": "10.3748", "volume": "25", "author": [{"given": "Nicole", "family": "Loo", "sequence": "first", "affiliation": []}, {"given": "Eric", "family": "Lawitz", "sequence": "additional", "affiliation": []}, {"given": "Naim", "family": "Alkhouri", "sequence": "additional", "affiliation": []}, {"given": "Jennifer", "family": "Wells", "sequence": "additional", "affiliation": []}, {"given": "Carmen", "family": "Landaverde", "sequence": "additional", "affiliation": []}, {"given": "Angie", "family": "Coste", "sequence": "additional", "affiliation": []}, {"given": "Rossalynn", "family": "Salcido", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Scott", "sequence": "additional", "affiliation": []}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": []}], "member": "2060", "container-title": ["World Journal of Gastroenterology"], "link": [{"URL": "https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 14]], "date-time": "2019-05-14T07:28:58Z", "timestamp": 1557818938000}, "score": 38.920464, "issued": {"date-parts": [[2019, 5, 14]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2019, 5, 14]]}, "issue": "18"}, "URL": "http://dx.doi.org/10.3748/wjg.v25.i18.2229", "ISSN": ["1007-9327"], "issn-type": [{"value": "1007-9327", "type": "print"}], "subject": ["Gastroenterology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T11:15:57Z", "timestamp": 1574507757102}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 3, 1]], "date-time": "2011-03-01T00:00:00Z", "timestamp": 1298937600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Hepatology"], "published-print": {"date-parts": [[2011, 3]]}, "DOI": "10.1016/s0168-8278(11)61222-1", "type": "journal-article", "created": {"date-parts": [[2011, 4, 21]], "date-time": "2011-04-21T05:50:57Z", "timestamp": 1303365057000}, "page": "S482", "source": "Crossref", "is-referenced-by-count": 6, "title": ["1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS"], "prefix": "10.1016", "volume": "54", "author": [{"given": "E.", "family": "Lawitz", "sequence": "first", "affiliation": []}, {"given": "I.", "family": "Gaultier", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Poordad", "sequence": "additional", "affiliation": []}, {"given": "D.E.", "family": "Cohen", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Menon", "sequence": "additional", "affiliation": []}, {"given": "L.M.", "family": "Larsen", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Podsadecki", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Bernstein", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Hepatology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0168827811612221?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0168827811612221?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 3]], "date-time": "2018-12-03T08:28:30Z", "timestamp": 1543825710000}, "score": 38.577496, "issued": {"date-parts": [[2011, 3]]}, "references-count": 0, "alternative-id": ["S0168827811612221"], "URL": "http://dx.doi.org/10.1016/s0168-8278(11)61222-1", "ISSN": ["0168-8278"], "issn-type": [{"value": "0168-8278", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T05:34:54Z", "timestamp": 1575437694799}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 4, 1]], "date-time": "2019-04-01T00:00:00Z", "timestamp": 1554076800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Hepatology"], "published-print": {"date-parts": [[2019, 4]]}, "DOI": "10.1016/s0618-8278(19)31488-4", "type": "journal-article", "created": {"date-parts": [[2019, 4, 16]], "date-time": "2019-04-16T06:29:11Z", "timestamp": 1555396151000}, "page": "e745-e746", "source": "Crossref", "is-referenced-by-count": 0, "title": ["SAT-255-Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir \u00b1 ribavirin in the TOPAZ-I and TOPAZ-II trials"], "prefix": "10.1016", "volume": "70", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "Rui Sarmento E.", "family": "Castro", "sequence": "additional", "affiliation": []}, {"given": "Armen", "family": "Asatryan", "sequence": "additional", "affiliation": []}, {"given": "Humberto", "family": "Aguilar", "sequence": "additional", "affiliation": []}, {"given": "Patrice", "family": "Cacoub", "sequence": "additional", "affiliation": []}, {"given": "Douglas", "family": "Dieterich", "sequence": "additional", "affiliation": []}, {"given": "Rui", "family": "Marinho", "sequence": "additional", "affiliation": []}, {"given": "Armando", "family": "Carvalho", "sequence": "additional", "affiliation": []}, {"given": "Asma", "family": "Siddique", "sequence": "additional", "affiliation": []}, {"given": "Yiran", "family": "Hu", "sequence": "additional", "affiliation": []}, {"given": "Mariem", "family": "Charafeddine", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Bondin", "sequence": "additional", "affiliation": []}, {"given": "Nader", "family": "Khan", "sequence": "additional", "affiliation": []}, {"given": "Daniel", "family": "Cohen", "sequence": "additional", "affiliation": []}, {"given": "Franco", "family": "Felizarta", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Hepatology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0618827819314884?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0618827819314884?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 5]], "date-time": "2019-06-05T13:55:56Z", "timestamp": 1559742956000}, "score": 38.538784, "issued": {"date-parts": [[2019, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2019, 4]]}, "issue": "1"}, "alternative-id": ["S0618827819314884"], "URL": "http://dx.doi.org/10.1016/s0618-8278(19)31488-4", "ISSN": ["0168-8278"], "issn-type": [{"value": "0168-8278", "type": "print"}], "subject": ["Hepatology"]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T17:23:36Z", "timestamp": 1574702616842}, "reference-count": 94, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1", "start": {"date-parts": [[2016, 9, 29]], "date-time": "2016-09-29T00:00:00Z", "timestamp": 1475107200000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "start": {"date-parts": [[2016, 9, 29]], "date-time": "2016-09-29T00:00:00Z", "timestamp": 1475107200000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Liver Int"], "published-print": {"date-parts": [[2017, 1]]}, "DOI": "10.1111/liv.13212", "type": "journal-article", "created": {"date-parts": [[2016, 9, 29]], "date-time": "2016-09-29T19:28:20Z", "timestamp": 1475177300000}, "page": "5-18", "source": "Crossref", "is-referenced-by-count": 46, "title": ["Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection"], "prefix": "10.1111", "volume": "37", "author": [{"given": "Jordan J.", "family": "Feld", "sequence": "first", "affiliation": [{"name": "Toronto Centre for Liver Disease; Toronto General Hospital; Toronto ON Canada"}]}, {"given": "Ira M.", "family": "Jacobson", "sequence": "additional", "affiliation": [{"name": "Mount Sinai Beth Israel; New York NY USA"}]}, {"given": "Mark S.", "family": "Sulkowski", "sequence": "additional", "affiliation": [{"name": "Johns Hopkins University; Baltimore MD USA"}]}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX USA"}]}, {"given": "Fernando", "family": "Tatsch", "sequence": "additional", "affiliation": [{"name": "AbbVie Inc.; North Chicago IL USA"}]}, {"given": "Jean-Michel", "family": "Pawlotsky", "sequence": "additional", "affiliation": [{"name": "Department of Virology; National Reference Center for Viral Hepatitis B, C and Delta; H\u00f4pital Henri Mondor; Universit\u00e9 Paris-Est; Cr\u00e9teil France"}, {"name": "INSERM U955; Cr\u00e9teil France"}]}], "member": "311", "published-online": {"date-parts": [[2016, 9, 29]]}, "reference": [{"key": "10.1111/liv.13212-BIB0001|liv13212-cit-0001", "doi-asserted-by": "crossref", "first-page": "1485", "DOI": "10.1056/NEJM199811193392101", "article-title": "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group", "volume": "339", "author": "McHutchison", "year": "1998", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0002|liv13212-cit-0002", "doi-asserted-by": "crossref", "first-page": "975", "DOI": "10.1056/NEJMoa020047", "article-title": "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", "volume": "347", "author": "Fried", "year": "2002", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0003|liv13212-cit-0003", "doi-asserted-by": "crossref", "first-page": "1839", "DOI": "10.1056/NEJMoa0807650", "article-title": "Telaprevir and peginterferon with or without ribavirin for chronic HCV infection", "volume": "360", "author": "Hezode", "year": "2009", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0004|liv13212-cit-0004", "doi-asserted-by": "crossref", "first-page": "705", "DOI": "10.1016/S0140-6736(10)60934-8", "article-title": "Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial", "volume": "376", "author": "Kwo", "year": "2010", "journal-title": "Lancet"}, {"key": "10.1111/liv.13212-BIB0005|liv13212-cit-0005", "doi-asserted-by": "crossref", "first-page": "1292", "DOI": "10.1056/NEJMoa0908014", "article-title": "Telaprevir for previously treated chronic HCV infection", "volume": "362", "author": "McHutchison", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0006|liv13212-cit-0006", "doi-asserted-by": "crossref", "first-page": "1195", "DOI": "10.1056/NEJMoa1010494", "article-title": "Boceprevir for untreated chronic HCV genotype 1 infection", "volume": "364", "author": "Poordad", "year": "2011", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0007|liv13212-cit-0007", "doi-asserted-by": "crossref", "first-page": "1207", "DOI": "10.1056/NEJMoa1009482", "article-title": "Boceprevir for previously treated chronic HCV genotype 1 infection", "volume": "364", "author": "Bacon", "year": "2011", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0008|liv13212-cit-0008", "doi-asserted-by": "crossref", "first-page": "1035", "DOI": "10.1053/j.gastro.2013.07.051", "article-title": "Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection - a randomized trial", "volume": "145", "author": "Poordad", "year": "2013", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0009|liv13212-cit-0009", "doi-asserted-by": "crossref", "first-page": "897", "DOI": "10.7326/0003-4819-123-12-199512150-00001", "article-title": "Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial", "volume": "123", "author": "Di Bisceglie", "year": "1995", "journal-title": "Ann Intern Med"}, {"key": "10.1111/liv.13212-BIB0010|liv13212-cit-0010", "doi-asserted-by": "crossref", "first-page": "408", "DOI": "10.1016/S0168-8278(05)80550-1", "article-title": "Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon", "volume": "19", "author": "Camps", "year": "1993", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0011|liv13212-cit-0011", "doi-asserted-by": "crossref", "first-page": "591", "DOI": "10.1016/S0168-8278(96)80225-X", "article-title": "Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study", "volume": "25", "author": "Dusheiko", "year": "1996", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0012|liv13212-cit-0012", "doi-asserted-by": "crossref", "first-page": "1629", "DOI": "10.1093/cid/cit074", "article-title": "What the infectious disease physician needs to know about pegylated interferon and ribavirin", "volume": "56", "author": "Gara", "year": "2013", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/liv.13212-BIB0013|liv13212-cit-0013", "unstructured": "REBETOL US Prescribing Information Initial approval 1998 https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf"}, {"key": "10.1111/liv.13212-BIB0014|liv13212-cit-0014", "unstructured": "MODERIBA US Prescribing Information Initial approval 2002 http://www.rxabbvie.com/pdf/moderiba_PI.pdf"}, {"key": "10.1111/liv.13212-BIB0015|liv13212-cit-0015", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1056/NEJMoa1402454", "article-title": "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", "volume": "370", "author": "Afdhal", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0016|liv13212-cit-0016", "doi-asserted-by": "crossref", "first-page": "1483", "DOI": "10.1056/NEJMoa1316366", "article-title": "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", "volume": "370", "author": "Afdhal", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0017|liv13212-cit-0017", "doi-asserted-by": "crossref", "first-page": "1879", "DOI": "10.1056/NEJMoa1402355", "article-title": "Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis", "volume": "370", "author": "Kowdley", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0018|liv13212-cit-0018", "unstructured": "HARVONI US Prescribing Information Initial approval 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf"}, {"key": "10.1111/liv.13212-BIB0019|liv13212-cit-0019", "unstructured": "HARVONI EU Summary of Product Characteristics Initial approval 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf"}, {"key": "10.1111/liv.13212-BIB0020|liv13212-cit-0020", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1016/S1473-3099(15)70050-2", "article-title": "Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)", "volume": "15", "author": "Bourliere", "year": "2015", "journal-title": "Lancet Infect Dis"}, {"key": "10.1111/liv.13212-BIB0021|liv13212-cit-0021", "doi-asserted-by": "crossref", "first-page": "79", "DOI": "10.1002/hep.27826", "article-title": "Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis", "volume": "62", "author": "Reddy", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0022|liv13212-cit-0022", "doi-asserted-by": "crossref", "first-page": "199", "DOI": "10.1016/j.jhep.2015.03.025", "article-title": "EASL Recommendations on Treatment of Hepatitis C 2015", "volume": "63", "author": "European Association for the Study of the Liver", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0023|liv13212-cit-0023", "unstructured": "AASLD-IDSA Guidance Panel HCV guidance: recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org/"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0024|liv13212-cit-0024", "first-page": "755A", "article-title": "Effectiveness of 12 or 24\u00a0week LDV/SOF and 12\u00a0week LDV/SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: real-world experience from the TRIO Network (poster presentation)", "volume": "62", "author": "Curry", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0025|liv13212-cit-0025", "doi-asserted-by": "crossref", "first-page": "S620", "DOI": "10.1016/S0168-8278(15)30976-4", "article-title": "The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with ledipasvir/sofosbuvir \u00b1 RBV", "volume": "62", "author": "Sarrazin", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0026|liv13212-cit-0026", "doi-asserted-by": "crossref", "first-page": "1594", "DOI": "10.1056/NEJMoa1315722", "article-title": "Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin", "volume": "370", "author": "Feld", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0027|liv13212-cit-0027", "doi-asserted-by": "crossref", "first-page": "1604", "DOI": "10.1056/NEJMoa1401561", "article-title": "Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin", "volume": "370", "author": "Zeuzem", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0028|liv13212-cit-0028", "unstructured": "VIEKIRA PAK US Prescribing Information Initial approval 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf"}, {"key": "10.1111/liv.13212-BIB0029|liv13212-cit-0029", "unstructured": "VIEKIRAX EU Summary of Product Characteristics Initial approval 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf"}, {"key": "10.1111/liv.13212-BIB0030|liv13212-cit-0030", "doi-asserted-by": "crossref", "first-page": "1983", "DOI": "10.1056/NEJMoa1402338", "article-title": "ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV", "volume": "370", "author": "Ferenci", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0031|liv13212-cit-0031", "doi-asserted-by": "crossref", "first-page": "359", "DOI": "10.1053/j.gastro.2014.04.045", "article-title": "ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection", "volume": "147", "author": "Andreone", "year": "2014", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0032|liv13212-cit-0032", "doi-asserted-by": "crossref", "first-page": "1973", "DOI": "10.1056/NEJMoa1402869", "article-title": "ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis", "volume": "370", "author": "Poordad", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0033|liv13212-cit-0033", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1016/j.jhep.2015.10.005", "article-title": "Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12\u00a0weeks", "volume": "64", "author": "Feld", "year": "2016", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0034|liv13212-cit-0034", "doi-asserted-by": "crossref", "first-page": "1756", "DOI": "10.1016/S0140-6736(14)61036-9", "article-title": "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study", "volume": "384", "author": "Lawitz", "year": "2014", "journal-title": "Lancet"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0035|liv13212-cit-0035", "doi-asserted-by": "crossref", "first-page": "S270", "DOI": "10.1016/S0168-8278(15)30168-9", "article-title": "A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12\u00a0weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na\u00efve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1", "volume": "62", "author": "Kwo", "year": "2015", "journal-title": "J Hepatol"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0036|liv13212-cit-0036", "doi-asserted-by": "crossref", "first-page": "S264", "DOI": "10.1016/S0168-8278(15)30158-6", "article-title": "A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12\u00a0weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-na\u00efve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2", "volume": "62", "author": "Lawitz", "year": "2015", "journal-title": "J Hepatol"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0037|liv13212-cit-0037", "first-page": "229A", "article-title": "An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with grazoprevir/elbasvir (oral presentation)", "volume": "62", "author": "Jacobson", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0038|liv13212-cit-0038", "first-page": "556", "article-title": "The combination of grazoprevir and elbasvir \u00b1 RBV is highly effective for the treatment of GT1a-infected patients (poster presentation)", "volume": "62", "author": "Thompson", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0039|liv13212-cit-0039", "first-page": "1393", "article-title": "Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection (late-breaking poster presentation)", "volume": "62", "author": "Jacobson", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0040|liv13212-cit-0040", "first-page": "555", "article-title": "High efficacy of the combination HCV regimen grazoprevir and elbasvir for 8 or 12\u00a0weeks with or without ribavirin in treatment-naive, noncirrhotic HCV GT1b-infected patients: an integrated analysis (poster presentation)", "volume": "62", "author": "Serfaty", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0041|liv13212-cit-0041", "doi-asserted-by": "crossref", "first-page": "S258", "DOI": "10.1016/S0168-8278(15)30149-5", "article-title": "Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER", "volume": "62", "author": "Pol", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0042|liv13212-cit-0042", "doi-asserted-by": "crossref", "first-page": "649", "DOI": "10.1053/j.gastro.2015.05.010", "article-title": "Ledipasvir\u00a0and sofosbuvir plus ribavirin for treatment of HCV infection with advanced liver disease", "volume": "149", "author": "Charlton", "year": "2015", "journal-title": "Gastroenterology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0043|liv13212-cit-0043", "doi-asserted-by": "crossref", "first-page": "S187", "DOI": "10.1016/S0168-8278(15)30003-9", "article-title": "Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial", "volume": "62", "author": "Manns", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0044|liv13212-cit-0044", "doi-asserted-by": "crossref", "first-page": "1493", "DOI": "10.1002/hep.28446", "article-title": "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence", "volume": "63", "author": "Poordad", "year": "2016", "journal-title": "Hepatology"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0045|liv13212-cit-0045", "doi-asserted-by": "crossref", "first-page": "S193", "DOI": "10.1016/S0168-8278(15)30015-5", "article-title": "Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child-pugh class B cirrhosis (C-SALT part A)", "volume": "62", "author": "Jacobson", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0046|liv13212-cit-0046", "doi-asserted-by": "crossref", "first-page": "2618", "DOI": "10.1056/NEJMoa1512614", "article-title": "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", "volume": "373", "author": "Curry", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0047|liv13212-cit-0047", "doi-asserted-by": "crossref", "first-page": "133", "DOI": "10.1002/cld.519", "article-title": "Treating hepatitis C virus in patients with decompensated cirrhosis: why is it so difficult and does a sustained response rate rescue the patient from liver transplantation?", "volume": "6", "author": "Kwo", "year": "2015", "journal-title": "Clin Liv Dis"}, {"key": "10.1111/liv.13212-BIB0048|liv13212-cit-0048", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1016/0016-5085(92)91129-R", "article-title": "Recurrent and acquired hepatitis C viral infection in liver transplant recipients", "volume": "103", "author": "Wright", "year": "1992", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0049|liv13212-cit-0049", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1053/j.gastro.2014.09.023", "article-title": "Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study", "volume": "148", "author": "Curry", "year": "2015", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0050|liv13212-cit-0050", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1053/j.gastro.2014.10.001", "article-title": "Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation", "volume": "148", "author": "Charlton", "year": "2015", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0051|liv13212-cit-0051", "doi-asserted-by": "crossref", "first-page": "2375", "DOI": "10.1056/NEJMoa1408921", "article-title": "An interferon-free antiviral regimen for HCV after liver transplantation", "volume": "371", "author": "Kwo", "year": "2014", "journal-title": "N Engl J Med"}, {"issue": "Suppl 1", "key": "10.1111/liv.13212-BIB0052|liv13212-cit-0052", "first-page": "742A", "article-title": "Ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin for patients with post-transplant HCV recurrence", "volume": "62", "author": "Mantry", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0053|liv13212-cit-0053", "first-page": "LB-4", "article-title": "Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study", "volume": "60", "author": "Brown", "year": "2014", "journal-title": "Hepatology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0054|liv13212-cit-0054", "first-page": "S187", "article-title": "The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large french prospective multicentric ANRS CO23 CUPILT cohort", "volume": "62", "author": "Coilly", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0055|liv13212-cit-0055", "unstructured": "University of Liverpool HEP Drug Interactions http://www.hep-druginteractions.org/"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0056|liv13212-cit-0056", "first-page": "716", "article-title": "RUBY-I: ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease", "volume": "62", "author": "Pockros", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0057|liv13212-cit-0057", "doi-asserted-by": "crossref", "first-page": "1590", "DOI": "10.1053/j.gastro.2016.02.078", "article-title": "Effect of direct-acting antiviral combination for patients with HCV genotype 1 infection and severe renal impairment or end-stage renal disease", "volume": "150", "author": "Pockros", "year": "2015", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0058|liv13212-cit-0058", "doi-asserted-by": "crossref", "first-page": "1075", "DOI": "10.1016/S0140-6736(14)61795-5", "article-title": "Efficacy and safety of 12\u00a0weeks versus 18\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial", "volume": "385", "author": "Lawitz", "year": "2015", "journal-title": "Lancet"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0059|liv13212-cit-0059", "doi-asserted-by": "crossref", "first-page": "S674", "DOI": "10.1016/S0168-8278(15)31088-6", "article-title": "Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 or 16\u00a0weeks in patients with HCV G1, G4 or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced", "volume": "62", "author": "Kwo", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0060|liv13212-cit-0060", "unstructured": "ClinicalTrials.gov Identifier NCT02487199 Ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with genotype 1a or genotype 4 chronic hepatitis C virus (HCV) infection, with severe kidney impairment or end stage kidney disease https://clinicaltrials.gov/ct2/show/NCT02487199?term=ombitasvir%2bRUBY%26rank=2"}, {"key": "10.1111/liv.13212-BIB0061|liv13212-cit-0061", "doi-asserted-by": "crossref", "first-page": "1537", "DOI": "10.1016/S0140-6736(15)00349-9", "article-title": "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study", "volume": "386", "author": "Roth", "year": "2015", "journal-title": "Lancet"}, {"key": "10.1111/liv.13212-BIB0062|liv13212-cit-0062", "doi-asserted-by": "crossref", "first-page": "705", "DOI": "10.1056/NEJMoa1501315", "article-title": "Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1", "volume": "373", "author": "Naggie", "year": "2015", "journal-title": "N Engl J Med"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0063|liv13212-cit-0063", "doi-asserted-by": "crossref", "first-page": "S675", "DOI": "10.1016/S0168-8278(15)31089-8", "article-title": "C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV", "volume": "62", "author": "Rockstroh", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0064|liv13212-cit-0064", "doi-asserted-by": "crossref", "first-page": "714", "DOI": "10.1056/NEJMoa1503153", "article-title": "Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1", "volume": "373", "author": "Wyles", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/liv.13212-BIB0065|liv13212-cit-0065", "unstructured": "clinicaltrials.gov A two part, open-label study to evaluate the safety and effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 given with or without a drug called ribavirin in people with both hepatitis C virus genotype 1 or 4 infection and human immunodeficiency virus, type 1 infection (TURQUOISE-I) 2015 2015"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0066|liv13212-cit-0066", "first-page": "306A", "article-title": "Once daily sofosbuvir (GS-7977) plus ribavirin\u00a0in patients with\u00a0HCV genotypes 1,2, and 3: the ELECTRON trial", "volume": "56", "author": "Gane", "year": "2012", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0067|liv13212-cit-0067", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1056/NEJMoa1306218", "article-title": "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection", "volume": "370", "author": "Sulkowski", "year": "2014", "journal-title": "N Engl J Med"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0068|liv13212-cit-0068", "first-page": "739", "article-title": "All-oral treatment with daclatasvir plus sofosbuvir\u00a0\u00b1 ribavirin in HCV genotype 3-infected patients with advanced fibrosis or cirrhosis: an analysis of ALLY-3 and ALLY-3+ (poster presentation)", "volume": "64", "author": "Kowdley", "year": "2016", "journal-title": "J Hepatol"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0069|liv13212-cit-0069", "first-page": "225", "article-title": "<br />Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program (oral presentation)", "volume": "62", "author": "Welzel", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0070|liv13212-cit-0070", "doi-asserted-by": "crossref", "first-page": "2608", "DOI": "10.1056/NEJMoa1512612", "article-title": "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", "volume": "373", "author": "Foster", "year": "2015", "journal-title": "N Engl J Med"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0071|liv13212-cit-0071", "first-page": "337", "article-title": "SURVEYOR-II: high SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-na\u00efve and treatment-experienced patients with HCV genotype 3 infection", "volume": "62", "author": "Kwo", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl", "key": "10.1111/liv.13212-BIB0072|liv13212-cit-0072", "first-page": "339", "article-title": "SURVEYOR-II: high SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-na\u00efve and treatment-experienced patients with HCV genotype 2 infection", "volume": "62", "author": "Wyles", "year": "2015", "journal-title": "Hepatology"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0073|liv13212-cit-0073", "doi-asserted-by": "crossref", "first-page": "S399", "DOI": "10.1016/S0168-8278(16)00629-2", "article-title": "Resistance analysis in 1284 patients with genotype 1 to 6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4 studies", "volume": "64", "author": "Hezode", "year": "2016", "journal-title": "J Hepatol"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0074|liv13212-cit-0074", "doi-asserted-by": "crossref", "first-page": "S619", "DOI": "10.1016/S0168-8278(15)30974-0", "article-title": "C-SCAPE: efficacy and safety of 12\u00a0weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection", "volume": "62", "author": "Brown", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0075|liv13212-cit-0075", "doi-asserted-by": "crossref", "first-page": "2502", "DOI": "10.1016/S0140-6736(15)60159-3", "article-title": "Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis\u00a0C virus infection (PEARL-I): a randomised, open-label trial", "volume": "385", "author": "Hezode", "year": "2015", "journal-title": "Lancet"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0076|liv13212-cit-0076", "doi-asserted-by": "crossref", "first-page": "S219", "DOI": "10.1016/S0168-8278(15)30070-2", "article-title": "Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection", "volume": "62", "author": "Abergel", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1111/liv.13212-BIB0077|liv13212-cit-0077", "doi-asserted-by": "crossref", "first-page": "1426", "DOI": "10.1016/S0140-6736(98)07124-4", "article-title": "Randomised trial of interferon alpha2b plus ribavirin for 48\u00a0weeks or for 24\u00a0weeks versus interferon alpha2b plus placebo for 48\u00a0weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)", "volume": "352", "author": "Poynard", "year": "1998", "journal-title": "Lancet"}, {"key": "10.1111/liv.13212-BIB0078|liv13212-cit-0078", "doi-asserted-by": "crossref", "first-page": "736", "DOI": "10.1053/j.gastro.2013.11.007", "article-title": "Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection", "volume": "146", "author": "Gane", "year": "2014", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0079|liv13212-cit-0079", "first-page": "1145A", "article-title": "Safety of ABT-450/ritonavir/ombitasvir + dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from phase 2 and 3 trials", "volume": "60", "author": "Fried", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0080|liv13212-cit-0080", "doi-asserted-by": "crossref", "first-page": "1798", "DOI": "10.1002/hep.27724", "article-title": "Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials", "volume": "61", "author": "Younossi", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0081|liv13212-cit-0081", "doi-asserted-by": "crossref", "first-page": "1002", "DOI": "10.1053/jhep.2002.32672", "article-title": "Mechanism of action of ribavirin in the combination treatment of chronic HCV infection", "volume": "35", "author": "Lau", "year": "2002", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0082|liv13212-cit-0082", "doi-asserted-by": "crossref", "first-page": "8074", "DOI": "10.1128/JVI.75.17.8074-8081.2001", "article-title": "Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes", "volume": "75", "author": "Lanford", "year": "2001", "journal-title": "J Virol"}, {"key": "10.1111/liv.13212-BIB0083|liv13212-cit-0083", "doi-asserted-by": "crossref", "first-page": "87", "DOI": "10.1002/hep.20253", "article-title": "Effects of antiviral therapy on the cellular immune response in acute hepatitis C", "volume": "40", "author": "Rahman", "year": "2004", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0084|liv13212-cit-0084", "doi-asserted-by": "crossref", "first-page": "967", "DOI": "10.1038/nature04082", "article-title": "Mechanism of action of interferon and ribavirin in treatment of hepatitis C", "volume": "436", "author": "Feld", "year": "2005", "journal-title": "Nature"}, {"key": "10.1111/liv.13212-BIB0085|liv13212-cit-0085", "doi-asserted-by": "crossref", "first-page": "1356", "DOI": "10.1053/j.gastro.2011.12.064", "article-title": "Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?", "volume": "142", "author": "Feld", "year": "2012", "journal-title": "Gastroenterology"}, {"key": "10.1111/liv.13212-BIB0086|liv13212-cit-0086", "doi-asserted-by": "crossref", "first-page": "46094", "DOI": "10.1074/jbc.C100349200", "article-title": "Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin", "volume": "276", "author": "Maag", "year": "2001", "journal-title": "J Biol Chem"}, {"key": "10.1111/liv.13212-BIB0087|liv13212-cit-0087", "doi-asserted-by": "crossref", "first-page": "1160", "DOI": "10.1002/hep.27092", "article-title": "Ribavirin improves the IFN-y response of natural killer cells to IFN-based therapy of hepatitis C infection", "volume": "60", "author": "Werner", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0088|liv13212-cit-0088", "doi-asserted-by": "crossref", "first-page": "6895", "DOI": "10.1073/pnas.111085598", "article-title": "RNA virus error catastrophe: direct molecular test by using ribavirin", "volume": "98", "author": "Crotty", "year": "2001", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/liv.13212-BIB0089|liv13212-cit-0089", "doi-asserted-by": "crossref", "first-page": "6172", "DOI": "10.1128/JVI.02778-12", "article-title": "Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients", "volume": "87", "author": "Dietz", "year": "2013", "journal-title": "J Virol"}, {"key": "10.1111/liv.13212-BIB0090|liv13212-cit-0090", "doi-asserted-by": "crossref", "first-page": "922", "DOI": "10.1038/nature03153", "article-title": "Modelling how ribavirin improves interferon response rates in hepatitis C virus infection", "volume": "432", "author": "Dixit", "year": "2004", "journal-title": "Nature"}, {"key": "10.1111/liv.13212-BIB0091|liv13212-cit-0091", "doi-asserted-by": "crossref", "first-page": "1126", "DOI": "10.1002/hep.27186", "article-title": "The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?", "volume": "60", "author": "Mondelli", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0092|liv13212-cit-0092", "first-page": "200A", "article-title": "Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study", "volume": "60", "author": "Reddy", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1111/liv.13212-BIB0093|liv13212-cit-0093", "doi-asserted-by": "crossref", "first-page": "222", "DOI": "10.1056/NEJMoa1306227", "article-title": "Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1", "volume": "370", "author": "Kowdley", "year": "2014", "journal-title": "N Engl J Med"}, {"issue": "Suppl 2", "key": "10.1111/liv.13212-BIB0094|liv13212-cit-0094", "doi-asserted-by": "crossref", "first-page": "S261", "DOI": "10.1016/S0168-8278(15)30154-9", "article-title": "Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study", "volume": "62", "author": "Poordad", "year": "2015", "journal-title": "J Hepatol"}], "container-title": ["Liver International"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fliv.13212", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fliv.13212", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13212/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T23:59:41Z", "timestamp": 1498348781000}, "score": 38.402412, "issued": {"date-parts": [[2016, 9, 29]]}, "references-count": 94, "journal-issue": {"published-print": {"date-parts": [[2017, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/liv.13212", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1478-3223"], "issn-type": [{"value": "1478-3223", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T13:32:53Z", "timestamp": 1575293573098}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 4, 1]], "date-time": "2008-04-01T00:00:00Z", "timestamp": 1207008000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Gastroenterology"], "published-print": {"date-parts": [[2008, 4]]}, "DOI": "10.1016/s0016-5085(08)63883-4", "type": "journal-article", "created": {"date-parts": [[2008, 8, 1]], "date-time": "2008-08-01T09:04:43Z", "timestamp": 1217581483000}, "page": "A-830", "source": "Crossref", "is-referenced-by-count": 0, "title": ["W1007 Rapid Virologic Response to Peginterferon Alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virologic Response and Relapse"], "prefix": "10.1016", "volume": "134", "author": [{"given": "F. Fred", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "Chrispin", "family": "Kambili", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gastroenterology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0016508508638834?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0016508508638834?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 26]], "date-time": "2018-12-26T20:50:06Z", "timestamp": 1545857406000}, "score": 36.60641, "issued": {"date-parts": [[2008, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 4]]}, "issue": "4"}, "alternative-id": ["S0016508508638834"], "URL": "http://dx.doi.org/10.1016/s0016-5085(08)63883-4", "ISSN": ["0016-5085"], "issn-type": [{"value": "0016-5085", "type": "print"}], "subject": ["Gastroenterology"]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T14:44:40Z", "timestamp": 1575470680243}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 5, 1]], "date-time": "2014-05-01T00:00:00Z", "timestamp": 1398902400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Gastroenterology"], "published-print": {"date-parts": [[2014, 5]]}, "DOI": "10.1016/s0016-5085(14)63285-6", "type": "journal-article", "created": {"date-parts": [[2014, 5, 2]], "date-time": "2014-05-02T03:01:04Z", "timestamp": 1398999664000}, "page": "S-903", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)"], "prefix": "10.1016", "volume": "146", "author": [{"given": "Kris V.", "family": "Kowdley", "sequence": "first", "affiliation": []}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": []}, {"given": "Roger", "family": "Trinh", "sequence": "additional", "affiliation": []}, {"given": "Christophe", "family": "Hezode", "sequence": "additional", "affiliation": []}, {"given": "Stefan", "family": "Zeuzem", "sequence": "additional", "affiliation": []}, {"given": "Kosh", "family": "Agarwal", "sequence": "additional", "affiliation": []}, {"given": "Mitchell L.", "family": "Shiffman", "sequence": "additional", "affiliation": []}, {"given": "Heiner", "family": "Wedemeyer", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Berg", "sequence": "additional", "affiliation": []}, {"given": "Eric M.", "family": "Yoshida", "sequence": "additional", "affiliation": []}, {"given": "Xavier", "family": "Forns", "sequence": "additional", "affiliation": []}, {"given": "Sandra S.", "family": "Lovell", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "DaSilva-Tillmann", "sequence": "additional", "affiliation": []}, {"given": "Andrew L.", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Podsadecki", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gastroenterology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0016508514632856?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0016508514632856?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 4]], "date-time": "2018-10-04T11:59:44Z", "timestamp": 1538654384000}, "score": 35.956314, "issued": {"date-parts": [[2014, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2014, 5]]}, "issue": "5"}, "alternative-id": ["S0016508514632856"], "URL": "http://dx.doi.org/10.1016/s0016-5085(14)63285-6", "ISSN": ["0016-5085"], "issn-type": [{"value": "0016-5085", "type": "print"}], "subject": ["Gastroenterology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T06:44:46Z", "timestamp": 1574750686439}, "reference-count": 16, "publisher": "Wiley", "issue": "6", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2017, 5, 3]], "date-time": "2017-05-03T00:00:00Z", "timestamp": 1493769600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions", "start": {"date-parts": [[2017, 5, 3]], "date-time": "2017-05-03T00:00:00Z", "timestamp": 1493769600000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"DOI": "10.13039/100005564", "name": "Gilead Sciences", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Hepatology"], "published-print": {"date-parts": [[2017, 6]]}, "DOI": "10.1002/hep.29130", "type": "journal-article", "created": {"date-parts": [[2017, 2, 21]], "date-time": "2017-02-21T15:07:30Z", "timestamp": 1487689650000}, "page": "1803-1809", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus"], "prefix": "10.1002", "volume": "65", "author": [{"given": "Eric", "family": "Lawitz", "sequence": "first", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Jennifer", "family": "Wells", "sequence": "additional", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Robert H.", "family": "Hyland", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "Yin", "family": "Yang", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "Hadas", "family": "Dvory-Sobol", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "Luisa M.", "family": "Stamm", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "Diana M.", "family": "Brainard", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "John G.", "family": "McHutchison", "sequence": "additional", "affiliation": [{"name": "Gilead Sciences, Inc; Foster City CA"}]}, {"given": "Carmen", "family": "Landaverde", "sequence": "additional", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Julio", "family": "Gutierrez", "sequence": "additional", "affiliation": [{"name": "Texas Liver Institute; University of Texas Health Science Center; San Antonio TX"}]}], "member": "311", "published-online": {"date-parts": [[2017, 5, 3]]}, "reference": [{"key": "10.1002/hep.29130-BIB0001|hep29130-cit-0001", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1002/hep.27259", "article-title": "Global distribution and prevalence of hepatitis C virus genotypes", "volume": "61", "author": "Messina", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1002/hep.29130-BIB0002|hep29130-cit-0002", "doi-asserted-by": "crossref", "first-page": "345", "DOI": "10.1146/annurev-med-052915-015720", "article-title": "Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs", "volume": "68", "author": "Naggie", "year": "2017", "journal-title": "Annu Rev Med"}, {"key": "10.1002/hep.29130-BIB0003|hep29130-cit-0003", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1002/jcph.830", "article-title": "Reinventing HCV treatment: past and future perspectives", "volume": "57", "author": "Carter", "year": "2017", "journal-title": "J Clin Pharmacol"}, {"key": "10.1002/hep.29130-BIB0004|hep29130-cit-0004", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.2147/HMER.S55864", "article-title": "Interferon-free combination therapies for the treatment of hepatitis C: current insights", "volume": "7", "author": "Holmes", "year": "2015", "journal-title": "Hepat Med"}, {"key": "10.1002/hep.29130-BIB0005|hep29130-cit-0005", "year": "2016", "volume-title": "Epclusa (sofosbuvir and velpatasvir) tablets, for oral use. Full prescribing information"}, {"issue": "Suppl 2", "key": "10.1002/hep.29130-BIB0006|hep29130-cit-0006", "doi-asserted-by": "crossref", "first-page": "S681", "DOI": "10.1016/S0168-8278(15)31102-8", "article-title": "Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 [Abstract P0899]", "volume": "62", "author": "Taylor", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1002/hep.29130-BIB0007|hep29130-cit-0007", "doi-asserted-by": "crossref", "first-page": "893", "DOI": "10.1053/j.gastro.2016.07.039", "article-title": "Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial", "volume": "151", "author": "Lawitz", "year": "2016", "journal-title": "Gastroenterology"}, {"key": "10.1002/hep.29130-BIB0008|hep29130-cit-0008", "doi-asserted-by": "crossref", "first-page": "2618", "DOI": "10.1056/NEJMoa1512614", "article-title": "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", "volume": "373", "author": "Curry", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1002/hep.29130-BIB0009|hep29130-cit-0009", "doi-asserted-by": "crossref", "first-page": "153", "DOI": "10.1016/j.jhep.2016.09.001", "article-title": "EASL recommendations on treatment of hepatitis C 2016", "volume": "66", "author": "European Association for the Study of the Liver", "year": "2017", "journal-title": "J Hepatol"}, {"key": "10.1002/hep.29130-BIB0010|hep29130-cit-0010", "unstructured": "American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel HCV guidance: recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org 2016"}, {"key": "10.1002/hep.29130-BIB0011|hep29130-cit-0011", "doi-asserted-by": "crossref", "first-page": "S192", "DOI": "10.1016/S0168-8278(15)30012-X", "article-title": "Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofobsuvir for 24 weeks [Abstract O005]", "volume": "62", "author": "Lawitz", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1002/hep.29130-BIB0012|hep29130-cit-0012", "doi-asserted-by": "crossref", "first-page": "S763", "DOI": "10.1016/S0168-8278(16)01488-4", "article-title": "C-SWIFT retreatment final results: highly successful retreatment of GT1-infected patients with 12 weeks of elbasvir/grazoprevir plus sofosbuvir and ribavirin after failure of short-duration all-oral therapy [Abstract SAT-148]", "volume": "64", "author": "Lawitz", "year": "2016", "journal-title": "J Hepatol"}, {"key": "10.1002/hep.29130-BIB0013|hep29130-cit-0013", "doi-asserted-by": "crossref", "first-page": "S767", "DOI": "10.1016/S0168-8278(16)01496-3", "article-title": "Ombitasvir/paritaprevir, dasabuvir, and sofosbuvir treatment of patients with HCV genotype 1-infection who failed a prior course of DAA therapy: the QUARTZ-I study [Abstract SAT-156]", "volume": "64", "author": "Poordad", "year": "2016", "journal-title": "J Hepatol"}, {"key": "10.1002/hep.29130-BIB0014|hep29130-cit-0014", "doi-asserted-by": "crossref", "first-page": "5368", "DOI": "10.1128/AAC.00763-16", "article-title": "Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein", "volume": "60", "author": "Lawitz", "year": "2016", "journal-title": "Antimicrob Agents Chemother"}, {"issue": "Suppl 1", "key": "10.1002/hep.29130-BIB0015|hep29130-cit-0015", "first-page": "102A", "article-title": "Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: the phase 3 POLARIS-1 study [Abstract]", "volume": "63", "author": "Bourli\u00e8re", "year": "2016", "journal-title": "Hepatology"}, {"issue": "Suppl 1", "key": "10.1002/hep.29130-BIB0016|hep29130-cit-0016", "first-page": "59A", "article-title": "A randomized, controlled, phase 3 trial of sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir/velpatasvir for 12 weeks in direct acting antiviral-experienced patients with genotype 1-6 HCV infection: the POLARIS-4 study [Abstract]", "volume": "63", "author": "Zeuzem", "year": "2016", "journal-title": "Hepatology"}], "container-title": ["Hepatology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.29130", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/hep.29130", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 7]], "date-time": "2018-08-07T00:42:11Z", "timestamp": 1533602531000}, "score": 35.888786, "subtitle": ["Lawitz et al."], "issued": {"date-parts": [[2017, 5, 3]]}, "references-count": 16, "journal-issue": {"published-print": {"date-parts": [[2017, 6]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1002/hep.29130", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0270-9139"], "issn-type": [{"value": "0270-9139", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T22:18:14Z", "timestamp": 1574547494573}, "reference-count": 40, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 2, 1]], "date-time": "2015-02-01T00:00:00Z", "timestamp": 1422748800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-sa/3.0/", "start": {"date-parts": [[2014, 9, 23]], "date-time": "2014-09-23T00:00:00Z", "timestamp": 1411430400000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"DOI": "10.13039/100006483", "name": "AbbVie Inc", "doi-asserted-by": "crossref", "award": []}], "content-domain": {"domain": ["journalofinfection.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Journal of Infection"], "published-print": {"date-parts": [[2015, 2]]}, "DOI": "10.1016/j.jinf.2014.09.008", "type": "journal-article", "created": {"date-parts": [[2014, 9, 22]], "date-time": "2014-09-22T01:20:03Z", "timestamp": 1411348803000}, "page": "197-205", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection"], "prefix": "10.1016", "volume": "70", "author": [{"given": "Eric", "family": "Lawitz", "sequence": "first", "affiliation": []}, {"given": "Greg", "family": "Sullivan", "sequence": "additional", "affiliation": []}, {"given": "Maribel", "family": "Rodriguez-Torres", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Bennett", "sequence": "additional", "affiliation": []}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": []}, {"given": "Mudra", "family": "Kapoor", "sequence": "additional", "affiliation": []}, {"given": "Prajakta", "family": "Badri", "sequence": "additional", "affiliation": []}, {"given": "Andrew", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"suffix": "Jr.", "given": "Lino", "family": "Rodrigues", "sequence": "additional", "affiliation": []}, {"given": "Yiran", "family": "Hu", "sequence": "additional", "affiliation": []}, {"given": "Tami", "family": "Pilot-Matias", "sequence": "additional", "affiliation": []}, {"given": "Regis A.", "family": "Vilchez", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Infection"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0163445314002874?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0163445314002874?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 15]], "date-time": "2019-08-15T06:56:44Z", "timestamp": 1565852204000}, "score": 35.41802, "issued": {"date-parts": [[2015, 2]]}, "references-count": 40, "journal-issue": {"published-print": {"date-parts": [[2015, 2]]}, "issue": "2"}, "alternative-id": ["S0163445314002874"], "URL": "http://dx.doi.org/10.1016/j.jinf.2014.09.008", "ISSN": ["0163-4453"], "issn-type": [{"value": "0163-4453", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection", "name": "articletitle", "label": "Article Title"}, {"value": "Journal of Infection", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.jinf.2014.09.008", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T01:15:13Z", "timestamp": 1574298913252}, "reference-count": 41, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 5, 1]], "date-time": "2009-05-01T00:00:00Z", "timestamp": 1241136000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Curr hepatitis rep"], "published-print": {"date-parts": [[2009, 5]]}, "DOI": "10.1007/s11901-009-0010-1", "type": "journal-article", "created": {"date-parts": [[2009, 5, 5]], "date-time": "2009-05-05T09:46:23Z", "timestamp": 1241516783000}, "page": "66-72", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Viral-guided hepatitis C therapy"], "prefix": "10.1007", "volume": "8", "author": [{"given": "Fred", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "Nancy", "family": "Reau", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 5, 6]]}, "reference": [{"key": "10_CR1", "doi-asserted-by": "crossref", "first-page": "958", "DOI": "10.1016/S0140-6736(01)06102-5", "volume": "358", "author": "M.P. Manns", "year": "2001", "unstructured": "Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958\u2013965.", "journal-title": "Lancet"}, {"key": "10_CR2", "doi-asserted-by": "crossref", "first-page": "975", "DOI": "10.1056/NEJMoa020047", "volume": "347", "author": "M.W. Fried", "year": "2002", "unstructured": "Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975\u2013982.", "journal-title": "N Engl J Med"}, {"key": "10_CR3", "doi-asserted-by": "crossref", "first-page": "1766", "DOI": "10.1002/lt.21635", "volume": "14", "author": "B. Roche", "year": "2008", "unstructured": "Roche B, Sebagh M, Canfora ML, et al.: Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008, 14:1766\u20131777.", "journal-title": "Liver Transpl"}, {"key": "10_CR4", "doi-asserted-by": "crossref", "first-page": "438", "DOI": "10.1056/NEJMoa040842", "volume": "351", "author": "F.J. Torriani", "year": "2004", "unstructured": "Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438\u2013450.", "journal-title": "N Engl J Med"}, {"key": "10_CR5", "unstructured": "Sulkowski M, Lawitz E, Shiffman ML, et al.: Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 26, 2008.", "DOI": "10.1016/S0168-8278(08)60993-9", "doi-asserted-by": "crossref"}, {"key": "10_CR6", "doi-asserted-by": "crossref", "first-page": "1147", "DOI": "10.1002/hep.20119", "volume": "39", "author": "D.B. Strader", "year": "2004", "unstructured": "Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147\u20131171.", "journal-title": "Hepatology"}, {"issue": "Suppl4", "key": "10_CR7", "first-page": "A1868", "volume": "48", "author": "M. Sulkowski", "year": "2008", "unstructured": "Sulkowski M, Vierling JM, Brown K, et al.: Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (Peg) plus ribavirin (RBV): results of the IDEAL trial. Hepatology 2008, 48(Suppl 4):A1868.", "journal-title": "Hepatology"}, {"key": "10_CR8", "doi-asserted-by": "crossref", "first-page": "97", "DOI": "10.1016/j.jhep.2005.10.003", "volume": "44", "author": "S. Zeuzem", "year": "2006", "unstructured": "Zeuzem S, Buti M, Ferenci P, et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97\u2013103.", "journal-title": "J Hepatol"}, {"key": "10_CR9", "doi-asserted-by": "crossref", "first-page": "954", "DOI": "10.1002/hep.21159", "volume": "43", "author": "D.M. Jensen", "year": "2006", "unstructured": "Jensen DM, Morgan TR, Marcellin P, et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954\u2013960.", "journal-title": "Hepatology"}, {"key": "10_CR10", "doi-asserted-by": "crossref", "first-page": "346", "DOI": "10.7326/0003-4819-140-5-200403020-00010", "volume": "140", "author": "S.J. Hadziyannis", "year": "2004", "unstructured": "Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346\u2013355.", "journal-title": "Ann Intern Med"}, {"key": "10_CR11", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.1053/jhep.2003.50364", "volume": "38", "author": "G.L. Davis", "year": "2003", "unstructured": "Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in paotients with chronic hepatitis C. Hepatology 2003, 38:645\u2013652.", "journal-title": "Hepatology"}, {"key": "10_CR12", "first-page": "818A", "volume": "46", "author": "P. Marcellin", "year": "2007", "unstructured": "Marcellin P, Jensen DM, Hadziyannis SJ, Ferenci P: Differentiation of early virologic response (EVR) into RVR, complete EVR (CEVR) and partial EVR (PEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40kd) (Pegasys) and ribavirin (Copegus). Hepatology 2007, 46:818A.", "journal-title": "Hepatology"}, {"key": "10_CR13", "doi-asserted-by": "crossref", "first-page": "425", "DOI": "10.1016/j.jhep.2005.04.009", "volume": "43", "author": "P. Ferenci", "year": "2005", "unstructured": "Ferenci P, Fried MW, Shiffman ML, et al.: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425\u2013433.", "journal-title": "J Hepatol"}, {"key": "10_CR14", "doi-asserted-by": "crossref", "first-page": "43", "DOI": "10.1002/hep.22061", "volume": "47", "author": "A. Mangia", "year": "2008", "unstructured": "Mangia A, Minerva N, Bacca D, et al.: Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43\u201350.", "journal-title": "Hepatology"}, {"key": "10_CR15", "doi-asserted-by": "crossref", "first-page": "1086", "DOI": "10.1053/j.gastro.2006.02.015", "volume": "130", "author": "T. Berg", "year": "2006", "unstructured": "Berg T, von Wagner M, Nasser S, et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086\u20131097.", "journal-title": "Gastroenterology"}, {"key": "10_CR16", "doi-asserted-by": "crossref", "first-page": "1688", "DOI": "10.1002/hep.21919", "volume": "46", "author": "B.L. Pearlman", "year": "2007", "unstructured": "Pearlman BL, Ehleben C, Saifee S: Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688\u20131694.", "journal-title": "Hepatology"}, {"key": "10_CR17", "doi-asserted-by": "crossref", "first-page": "228", "DOI": "10.1111/j.1365-2893.2006.00779.x", "volume": "14", "author": "M. Crespo", "year": "2007", "unstructured": "Crespo M, Sauleda S, Esteban JI, et al.: Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007, 14:228\u2013238.", "journal-title": "J Viral Hepat"}, {"key": "10_CR18", "doi-asserted-by": "crossref", "first-page": "1111", "DOI": "10.1136/gut.2006.106690", "volume": "56", "author": "C. Payan", "year": "2007", "unstructured": "Payan C, Pivert A, Morand P, et al.: AnRS HC02 RIBAVIC study team: Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007, 56:1111\u20131116.", "journal-title": "Gut"}, {"key": "10_CR19", "doi-asserted-by": "crossref", "first-page": "964", "DOI": "10.1086/382279", "volume": "189", "author": "G.L. Drusano", "year": "2004", "unstructured": "Drusano GL, Preston SL: A 48-week duration of therapy with pegylated interferon afa 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004, 189:964\u2013970.", "journal-title": "J Infect Dis"}, {"key": "10_CR20", "doi-asserted-by": "crossref", "first-page": "580", "DOI": "10.1016/j.jhep.2007.07.015", "volume": "47", "author": "P. Marcellin", "year": "2007", "unstructured": "Marcellin P, Heathcote EJ, Craxi A: Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the \u201caccordion\u201d regimen? J Hepatol 2007, 47:580\u2013587.", "journal-title": "J Hepatol"}, {"key": "10_CR21", "doi-asserted-by": "crossref", "first-page": "S369", "DOI": "10.1016/S0168-8278(08)60990-3", "volume": "48", "author": "T. Poynard", "year": "2008", "unstructured": "Poynard T, Colombo M, Bruix J, et al.: Sustained viral response is dependent on baseline characteristics in the re-treatment of previous interferon/ribavirin nonresponders: final results from the EPIC 3 program. J Hepatol 2008, 48:S369.", "journal-title": "J Hepatol"}, {"key": "10_CR22", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1111/j.1365-2036.2008.03763.x", "volume": "28", "author": "A. Andriulli", "year": "2008", "unstructured": "Andriulli A, Mangia A, Iacobellis A, et al.: Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008, 28:397\u2013404.", "journal-title": "Aliment Pharmacol Ther"}, {"key": "10_CR23", "doi-asserted-by": "crossref", "first-page": "106", "DOI": "10.1016/S0168-8278(00)80166-X", "volume": "33", "author": "L. Rubbia-Brandt", "year": "2000", "unstructured": "Rubbia-Brandt L, Quadri R, Abid K, et al.: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106\u2013115.", "journal-title": "J Hepatol"}, {"key": "10_CR24", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1111/j.1478-3231.2008.01859.x", "volume": "29", "author": "M. Rodr\u00edguez-Torres", "year": "2009", "unstructured": "Rodr\u00edguez-Torres M, Govindarajan S, Diago M, et al.: Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int 2009, 29:237\u2013241.", "journal-title": "Liver Int"}, {"key": "10_CR25", "doi-asserted-by": "crossref", "first-page": "1576", "DOI": "10.1002/jmv.21253", "volume": "80", "author": "M. Rodr\u00edguez-Torres", "year": "2008", "unstructured": "Rodr\u00edguez-Torres M, R\u00edos-Bedoya CF, Ortiz-Lasanta G, et al.: Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks. J Med Virol 2008, 80:1576\u20131580.", "journal-title": "J Med Virol"}, {"key": "10_CR26", "doi-asserted-by": "crossref", "first-page": "761", "DOI": "10.1111/j.1572-0241.2007.01092.x", "volume": "102", "author": "M.L. Shiffman", "year": "2007", "unstructured": "Shiffman ML, Mihas AA, Millwala F, et al.: Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007, 102:761\u2013766.", "journal-title": "Am J Gastroenterol"}, {"key": "10_CR27", "first-page": "52", "volume": "15", "author": "J. Powis", "year": "2008", "unstructured": "Powis J, Peltekian KM, Lee SS, et al.: Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008, 15:52\u201357.", "journal-title": "J Viral Hepat"}, {"key": "10_CR28", "doi-asserted-by": "crossref", "first-page": "641", "DOI": "10.1111/j.1365-2893.2008.00999.x", "volume": "15", "author": "O. Weiland", "year": "2008", "unstructured": "Weiland O, Hollander A, Mattsson L, et al.: Lower-than-standard dose PEG-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008, 15:641\u2013645.", "journal-title": "J Viral Hepat"}, {"key": "10_CR29", "doi-asserted-by": "crossref", "first-page": "1816", "DOI": "10.1002/hep.22262", "volume": "47", "author": "P. Ferenci", "year": "2008", "unstructured": "Ferenci P, Brunner H, Laferl H, et al.: A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008, 47:1816\u20131823.", "journal-title": "Hepatology"}, {"key": "10_CR30", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1056/NEJMoa066403", "volume": "357", "author": "M.L. Shiffman", "year": "2007", "unstructured": "Shiffman ML, Suter F, Bacon BR, et al.: Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124\u2013134.", "journal-title": "N Engl J Med"}, {"key": "10_CR31", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1111/j.1365-2036.2008.03763.x", "volume": "28", "author": "A. Andriulli", "year": "2008", "unstructured": "Andriulli A, Mangia A, Iacobellis A, et al.: Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008, 28:397\u2013404.", "journal-title": "Aliment Pharmacol Ther"}, {"key": "10_CR32", "doi-asserted-by": "crossref", "first-page": "803", "DOI": "10.1002/jmv.21133", "volume": "80", "author": "T. Carlsson", "year": "2008", "unstructured": "Carlsson T, Quist A, Weiland O: Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol 2008, 80:803\u2013807.", "journal-title": "J Med Virol"}, {"key": "10_CR33", "doi-asserted-by": "crossref", "first-page": "1260", "DOI": "10.1002/hep.20467", "volume": "40", "author": "O. Dalgard", "year": "2004", "unstructured": "Dalgard O, Bj\u00f8ro K, Hellum KB, et al.: Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004, 40:1260\u20131265.", "journal-title": "Hepatology"}, {"key": "10_CR34", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1002/hep.21975", "volume": "47", "author": "O. Dalgard", "year": "2008", "unstructured": "Dalgard O, Bj\u00f8ro K, Ring-Larsen H, et al.: Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35\u201342.", "journal-title": "Hepatology"}, {"key": "10_CR35", "doi-asserted-by": "crossref", "first-page": "2609", "DOI": "10.1056/NEJMoa042608", "volume": "352", "author": "A. Mangia", "year": "2005", "unstructured": "Mangia A, Santoro R, Minerva N, et al.: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609\u20132617.", "journal-title": "N Engl J Med"}, {"key": "10_CR36", "doi-asserted-by": "crossref", "first-page": "522", "DOI": "10.1053/j.gastro.2005.05.008", "volume": "129", "author": "M. Wagner von", "year": "2005", "unstructured": "von Wagner M, Huber M, Berg T, et al.: Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522\u2013527.", "journal-title": "Gastroenterology"}, {"key": "10_CR37", "doi-asserted-by": "crossref", "first-page": "553", "DOI": "10.1136/gut.2006.102558", "volume": "56", "author": "M.L. Yu", "year": "2007", "unstructured": "Yu ML, Dai CY, Huang JF, et al.: A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007, 56:553\u2013559.", "journal-title": "Gut"}, {"key": "10_CR38", "doi-asserted-by": "crossref", "first-page": "1837", "DOI": "10.1002/hep.22253", "volume": "47", "author": "M. Lagging", "year": "2008", "unstructured": "Lagging M, Langeland N, Pedersen C, et al.: Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008, 47:1837\u20131845.", "journal-title": "Hepatology"}, {"key": "10_CR39", "doi-asserted-by": "crossref", "first-page": "719", "DOI": "10.1007/s10620-005-2563-3", "volume": "50", "author": "S.K. Herrine", "year": "2005", "unstructured": "Herrine SK, Brown RS Jr, Bernstein DE, et al.: Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005, 50:719\u2013726.", "journal-title": "Dig Dis Sci"}, {"key": "10_CR40", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1016/j.dld.2006.08.007", "volume": "39", "author": "M. Basso", "year": "2007", "unstructured": "Basso M, Torre F, Grasso A, et al.: Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis 2007, 39:47\u201351.", "journal-title": "Dig Liver Dis"}, {"key": "10_CR41", "doi-asserted-by": "crossref", "first-page": "435", "DOI": "10.1111/j.1365-2893.2006.00727.x", "volume": "13", "author": "C. Berg", "year": "2006", "unstructured": "Berg C, Goncales FL, Bernstein DE, et al.: Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006, 13:435\u2013440.", "journal-title": "J Viral Hepat"}], "container-title": ["Current Hepatitis Reports"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s11901-009-0010-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s11901-009-0010-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s11901-009-0010-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T00:08:27Z", "timestamp": 1559434107000}, "score": 34.61028, "issued": {"date-parts": [[2009, 5]]}, "references-count": 41, "journal-issue": {"published-print": {"date-parts": [[2009, 5]]}, "issue": "2"}, "alternative-id": ["10"], "URL": "http://dx.doi.org/10.1007/s11901-009-0010-1", "relation": {"cites": []}, "ISSN": ["1540-3416", "1541-0706"], "issn-type": [{"value": "1540-3416", "type": "print"}, {"value": "1541-0706", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T03:38:17Z", "timestamp": 1574739497315}, "reference-count": 9, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Liver Disease"], "published-print": {"date-parts": [[2015, 10]]}, "DOI": "10.1002/cld.506", "type": "journal-article", "created": {"date-parts": [[2015, 10, 28]], "date-time": "2015-10-28T22:56:12Z", "timestamp": 1446072972000}, "page": "79-81", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Treatment of patients with hepatitis C virus genotype 3: Where are we now?"], "prefix": "10.1002", "volume": "6", "author": [{"given": "Carmen", "family": "Landaverde", "sequence": "first", "affiliation": [{"name": "The Texas Liver Institute/University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Jennifer T.", "family": "Wells", "sequence": "additional", "affiliation": [{"name": "The Texas Liver Institute/University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Julio", "family": "Gutierrez", "sequence": "additional", "affiliation": [{"name": "The Texas Liver Institute/University of Texas Health Science Center; San Antonio TX"}]}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": [{"name": "The Texas Liver Institute/University of Texas Health Science Center; San Antonio TX"}]}], "member": "311", "published-online": {"date-parts": [[2015, 10, 28]]}, "reference": [{"key": "10.1002/cld.506-BIB0001|cld506-cit-0001", "doi-asserted-by": "crossref", "first-page": "1142", "DOI": "10.1016/j.jhep.2009.01.019", "article-title": "Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis", "volume": "50", "author": "Raimondi", "year": "2009", "journal-title": "J Hepatol"}, {"key": "10.1002/cld.506-BIB0002|cld506-cit-0002", "doi-asserted-by": "crossref", "first-page": "98", "DOI": "10.1002/hep.27095", "article-title": "HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV", "volume": "60", "author": "Kanwal", "year": "2014", "journal-title": "Hepatology"}, {"key": "10.1002/cld.506-BIB0003|cld506-cit-0003", "unstructured": "American Association for the Study of Liver Diseases/Infectious Diseases Society of America. http://www.hcvguidelines.org/full-report/initial-treatment-box-summary-recommendations-patients-who-are-initiating-therapy-hcv"}, {"key": "10.1002/cld.506-BIB0004|cld506-cit-0004", "doi-asserted-by": "crossref", "first-page": "S259", "DOI": "10.1016/S0168-8278(15)30151-3", "article-title": "Sofosbuvir plus Peg-IFN/RBV for 12 weeks vs sofosbuvir/RBV for 16 or 24 weeks in genotype 3 HCV-infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The BOSON Study [Abstract L05]", "volume": "62", "author": "Foster", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1002/cld.506-BIB0005|cld506-cit-0005", "doi-asserted-by": "crossref", "first-page": "S192", "DOI": "10.1016/S0168-8278(15)30012-X", "article-title": "Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [Abstract O005]", "volume": "62", "author": "Lawitz", "year": "2015", "journal-title": "J Hepatol"}, {"key": "10.1002/cld.506-BIB0007|cld506-cit-0007", "doi-asserted-by": "crossref", "first-page": "1127", "DOI": "10.1002/hep.27726", "article-title": "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study", "volume": "61", "author": "Nelson", "year": "2015", "journal-title": "Hepatology"}, {"key": "10.1002/cld.506-BIB0008|cld506-cit-0008", "doi-asserted-by": "crossref", "first-page": "S265", "DOI": "10.1016/S0168-8278(15)30159-8", "article-title": "Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program [Abstract LP05]", "volume": "62", "author": "Hezode", "year": "2015", "journal-title": "J Hepatol"}, {"issue": "suppl", "key": "10.1002/cld.506-BIB0009|cld506-cit-0009", "doi-asserted-by": "crossref", "first-page": "S3", "DOI": "10.1016/S0168-8278(14)60008-8", "article-title": "Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience [Abstract O6]", "volume": "60", "author": "Gane", "year": "2014", "journal-title": "J Hepatol"}, {"key": "10.1002/cld.506-BIB0010|cld506-cit-0010", "doi-asserted-by": "crossref", "first-page": "S192", "DOI": "10.1016/S0168-8278(15)30013-1", "article-title": "C-SWIFT: grazoprevir/elbasvir\u2009+\u2009sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis c virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks [Abstract O006]", "volume": "62", "author": "Poordad", "year": "2015", "journal-title": "J Hepatol"}], "container-title": ["Clinical Liver Disease"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.506", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/cld.506", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 6]], "date-time": "2018-08-06T00:36:01Z", "timestamp": 1533515761000}, "score": 34.266838, "subtitle": ["Treatment of Patients with HCV Genotype 3"], "issued": {"date-parts": [[2015, 10]]}, "references-count": 9, "journal-issue": {"published-print": {"date-parts": [[2015, 10]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1002/cld.506", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["2046-2484"], "issn-type": [{"value": "2046-2484", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T16:40:59Z", "timestamp": 1574786459162}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2016, 4, 1]], "date-time": "2016-04-01T00:00:00Z", "timestamp": 1459468800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Gastroenterology"], "published-print": {"date-parts": [[2016, 4]]}, "DOI": "10.1016/s0016-5085(16)33693-9", "type": "journal-article", "created": {"date-parts": [[2016, 4, 18]], "date-time": "2016-04-18T08:18:59Z", "timestamp": 1460967539000}, "page": "S1093", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Su1416 Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1 - 6 Infection: Results From the SURVEYOR-I and SURVEYOR-II Studies"], "prefix": "10.1016", "volume": "150", "author": [{"given": "Paul Y.", "family": "Kwo", "sequence": "first", "affiliation": []}, {"given": "Fred", "family": "Poordad", "sequence": "additional", "affiliation": []}, {"given": "Ariel R.", "family": "Porcalla", "sequence": "additional", "affiliation": []}, {"given": "Edward", "family": "Gane", "sequence": "additional", "affiliation": []}, {"given": "Jacob", "family": "Lalezari", "sequence": "additional", "affiliation": []}, {"given": "David L.", "family": "Wyles", "sequence": "additional", "affiliation": []}, {"given": "Ran", "family": "Liu", "sequence": "additional", "affiliation": []}, {"given": "Jens", "family": "Kort", "sequence": "additional", "affiliation": []}, {"given": "Federico", "family": "Mensa", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Gastroenterology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0016508516336939?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0016508516336939?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 13]], "date-time": "2018-09-13T08:27:02Z", "timestamp": 1536827222000}, "score": 34.215855, "issued": {"date-parts": [[2016, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2016, 4]]}, "issue": "4"}, "alternative-id": ["S0016508516336939"], "URL": "http://dx.doi.org/10.1016/s0016-5085(16)33693-9", "ISSN": ["0016-5085"], "issn-type": [{"value": "0016-5085", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T16:42:56Z", "timestamp": 1574700176039}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Hepatology"], "published-print": {"date-parts": [[2016]]}, "DOI": "10.1016/s0168-8278(16)00170-7", "type": "journal-article", "created": {"date-parts": [[2016, 9, 22]], "date-time": "2016-09-22T20:00:12Z", "timestamp": 1474574412000}, "page": "S208", "source": "Crossref", "is-referenced-by-count": 9, "title": ["100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Na\u00efve HCV Genotype 3-Infected Patients with Cirrhosis"], "prefix": "10.1016", "volume": "64", "author": [{"given": "P.Y.", "family": "Kwo", "sequence": "first", "affiliation": []}, {"given": "D.L.", "family": "Wyles", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Wang", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Poordad", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Gane", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Maliakkal", "sequence": "additional", "affiliation": []}, {"given": "M.L.", "family": "Shiffman", "sequence": "additional", "affiliation": []}, {"given": "T.I.", "family": "Ng", "sequence": "additional", "affiliation": []}, {"given": "C.-W.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Liu", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Kort", "sequence": "additional", "affiliation": []}, {"given": "F.J.", "family": "Mensa", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Hepatology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0168827816001707?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0168827816001707?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 8]], "date-time": "2018-09-08T06:26:23Z", "timestamp": 1536387983000}, "score": 33.73025, "issued": {"date-parts": [[2016]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2016]]}, "issue": "2"}, "alternative-id": ["S0168827816001707"], "URL": "http://dx.doi.org/10.1016/s0168-8278(16)00170-7", "ISSN": ["0168-8278"], "issn-type": [{"value": "0168-8278", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T14:05:56Z", "timestamp": 1575468356481}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 4, 1]], "date-time": "2014-04-01T00:00:00Z", "timestamp": 1396310400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Hepatology"], "published-print": {"date-parts": [[2014, 4]]}, "DOI": "10.1016/s0168-8278(14)61458-6", "type": "journal-article", "created": {"date-parts": [[2014, 4, 24]], "date-time": "2014-04-24T09:17:52Z", "timestamp": 1398331072000}, "page": "S523", "source": "Crossref", "is-referenced-by-count": 2, "title": ["O163 TURQUOISE-II: SVR12 RATES OF 92\u201396% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)"], "prefix": "10.1016", "volume": "60", "author": [{"given": "F.", "family": "Poordad", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Hezode", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Trinh", "sequence": "additional", "affiliation": []}, {"given": "K.V.", "family": "Kowdley", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Zeuzem", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Agarwal", "sequence": "additional", "affiliation": []}, {"given": "M.L.", "family": "Shiffman", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Wedemeyer", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Berg", "sequence": "additional", "affiliation": []}, {"given": "E.M.", "family": "Yoshida", "sequence": "additional", "affiliation": []}, {"given": "X.", "family": "Forns", "sequence": "additional", "affiliation": []}, {"given": "S.S.", "family": "Lovell", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Da Silva-Tillmann", "sequence": "additional", "affiliation": []}, {"given": "A.L.", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Podsadecki", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Hepatology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0168827814614586?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0168827814614586?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 4]], "date-time": "2018-10-04T17:55:14Z", "timestamp": 1538675714000}, "score": 33.474205, "issued": {"date-parts": [[2014, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2014, 4]]}, "issue": "1"}, "alternative-id": ["S0168827814614586"], "URL": "http://dx.doi.org/10.1016/s0168-8278(14)61458-6", "ISSN": ["0168-8278"], "issn-type": [{"value": "0168-8278", "type": "print"}], "subject": ["Hepatology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}